Acronyms of Clinical Trial Names: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 2,283: | Line 2,283: | ||
| [[A Randomized, Multicenter Study Of The Pimecrolimus-Eluting And Pimecrolimus/Paclitaxel-Eluting Coronary Stent System In Patients With De Novo Lesions Of The Native Coronary Arteries]] | | [[A Randomized, Multicenter Study Of The Pimecrolimus-Eluting And Pimecrolimus/Paclitaxel-Eluting Coronary Stent System In Patients With De Novo Lesions Of The Native Coronary Arteries]] | ||
|- | |- | ||
| GENEVA | | [[GENEVA]] | ||
| [[ Intracoronary Beta Irradiation To Reduce Restenosis After Balloon Angioplasty]] | | [[ Intracoronary Beta Irradiation To Reduce Restenosis After Balloon Angioplasty]] | ||
|- | |- | ||
| GENIUS-STEMI | | [[GENIUS-STEMI]] | ||
| [[A Randomized Comparison Of Genous Stent Versus Chromium-Cobalt Stent For Treatment Of St-Elevation Myocardial Infarction]] | | [[A Randomized Comparison Of Genous Stent Versus Chromium-Cobalt Stent For Treatment Of St-Elevation Myocardial Infarction]] | ||
|- | |- | ||
| GenSalt | | [[GenSalt]] | ||
| [[Genetic Epidemiology Network Of Salt Sensitivity]] | | [[Genetic Epidemiology Network Of Salt Sensitivity]] | ||
|- | |- | ||
| GESICA | | [[GESICA]] | ||
| [[Randomized Trial Of Low-Dose Amiodarone In Severe Congestive Heart Failure]] | | [[Randomized Trial Of Low-Dose Amiodarone In Severe Congestive Heart Failure]] | ||
|- | |- | ||
| GIPS | | [[GIPS]] | ||
| [[Randomized Trial Of Glucose-Insulin-Potassium Infusion On 30 Day Mortality In Patients With Acute Myocardial Infarction Treated With Primary Angioplasty]] | | [[Randomized Trial Of Glucose-Insulin-Potassium Infusion On 30 Day Mortality In Patients With Acute Myocardial Infarction Treated With Primary Angioplasty]] | ||
|- | |- | ||
| GIPS II | | [[GIPS II]] | ||
| [[ Glucose - Insulin - Potassium Study In Patients With St Elevation Myocardial Infarction Without Signs Of Heart Failure]] | | [[ Glucose - Insulin - Potassium Study In Patients With St Elevation Myocardial Infarction Without Signs Of Heart Failure]] | ||
|- | |- | ||
| GISEN | | [[GISEN]] | ||
| [[Gruppo Italiano Di Studi Epidemiologici In Nefrologia]] | | [[Gruppo Italiano Di Studi Epidemiologici In Nefrologia]] | ||
|- | |- | ||
| GISSI-1 | | [[GISSI-1]] | ||
| [[Gruppo Italiano Per Lo Studio Della Sopravvivenza Nell'Infarto Miocardico Acuto-1]] | | [[Gruppo Italiano Per Lo Studio Della Sopravvivenza Nell'Infarto Miocardico Acuto-1]] | ||
|- | |- | ||
| GISSI-2 | | [[GISSI-2]] | ||
| [[Gruppo Italiano Per Lo Studio Della Sopravvivenza Nell'Infarto Miocardico Acuto-2]] | | [[Gruppo Italiano Per Lo Studio Della Sopravvivenza Nell'Infarto Miocardico Acuto-2]] | ||
|- | |- | ||
| GISSI-3 | | [[GISSI-3]] | ||
| [[Effects Of Lisinopril And Transdermal Glycerol Trinitrate Singly And Together On 6-Week Mortality And Ventricular Function After Ami]] | | [[Effects Of Lisinopril And Transdermal Glycerol Trinitrate Singly And Together On 6-Week Mortality And Ventricular Function After Ami]] | ||
|- | |- | ||
| GISSI-HF: n-3 PUFA | | [[GISSI-HF: n-3 PUFA]] | ||
| [[Gruppo Italiano Per Lo Studio Della Sopravvivenza Nell’Infarto Miocardico–Heart Failure: N-3 Pufa]] | | [[Gruppo Italiano Per Lo Studio Della Sopravvivenza Nell’Infarto Miocardico–Heart Failure: N-3 Pufa]] | ||
|- | |- | ||
| GISSI-HF: Rosuvastatin | | [[GISSI-HF: Rosuvastatin]] | ||
| [[Gruppo Italiano Per Lo Studio Della Sopravvivenza Nell’Infarto Miocardico–Heart Failure: Rosuvastatin]] | | [[Gruppo Italiano Per Lo Studio Della Sopravvivenza Nell’Infarto Miocardico–Heart Failure: Rosuvastatin]] | ||
|- | |- | ||
| GOSPEL | | [[GOSPEL]] | ||
| [[Global Secondary Prevention Strategies To Limit Event Recurrence After Myocardial Infarction]] | | [[Global Secondary Prevention Strategies To Limit Event Recurrence After Myocardial Infarction]] | ||
|- | |- | ||
| G-PAD | | [[G-PAD]] | ||
| [[Granulocyte-Macrophage Colony Stimulating Factor In Patients With Intermittent Claudication]] | | [[Granulocyte-Macrophage Colony Stimulating Factor In Patients With Intermittent Claudication]] | ||
|- | |- | ||
| GRACIA I | | [[GRACIA I]] | ||
| [[Randomized Trial Comparing Stenting Within 24 Hours Of Thrombolysis Versus Ischemia-Guided Approach To Thrombolysed Acute Myocardial Infarction With St Elevation]] | | [[Randomized Trial Comparing Stenting Within 24 Hours Of Thrombolysis Versus Ischemia-Guided Approach To Thrombolysed Acute Myocardial Infarction With St Elevation]] | ||
|- | |- | ||
| GRACIA II | | [[GRACIA II]] | ||
| [[Primary Optimal Percutaneous Coronary Intervention Versus Facilitated Intervention In Stemi Patients]] | | [[Primary Optimal Percutaneous Coronary Intervention Versus Facilitated Intervention In Stemi Patients]] | ||
|- | |- | ||
| GRAPE | | [[GRAPE]] | ||
| [[Grampian Region Early Anistreplase Trial]] | | [[Grampian Region Early Anistreplase Trial]] | ||
|- | |- | ||
| GUARDIAN | | [[GUARDIAN]] | ||
| [[Inhibition Of The Sodium-Hydrogen Exchanger With Cariporide To Prevent Myocardial Infarction In High-Risk Ischemic Situations: Main Results Of The Guard During Ischemia Against Necrosis (Guardian) Trial]] | | [[Inhibition Of The Sodium-Hydrogen Exchanger With Cariporide To Prevent Myocardial Infarction In High-Risk Ischemic Situations: Main Results Of The Guard During Ischemia Against Necrosis (Guardian) Trial]] | ||
|- | |- | ||
| GUSTO | | [[GUSTO]] | ||
| [[Global Utilization Of Streptokinase And Tpa For Occluded Arteries ]] | | [[Global Utilization Of Streptokinase And Tpa For Occluded Arteries ]] | ||
|- | |- | ||
| GUSTO IIB | | [[GUSTO IIB]] | ||
| [[Global Utilization Of Streptokinase And Tpa For Occluded Arteries IIb]] | | [[Global Utilization Of Streptokinase And Tpa For Occluded Arteries IIb]] | ||
|- | |- | ||
| GUSTO V | | [[GUSTO V]] | ||
| [[The Gusto V Randomised Trial]] | | [[The Gusto V Randomised Trial]] | ||
|- | |- | ||
| GUSTO-3 | | [[GUSTO-3]] | ||
| [[Global Utilization Of Streptokinase And Tpa For Occluded Arteries-III]] | | [[Global Utilization Of Streptokinase And Tpa For Occluded Arteries-III]] | ||
|- | |- | ||
| GUSTO-SPEED | | [[GUSTO-SPEED]] | ||
| [[Global Utilization Of Streptokinase And Tpa For Occluded Arteries–Strategies For Patency Enhancement In The Emergency Department]] | | [[Global Utilization Of Streptokinase And Tpa For Occluded Arteries–Strategies For Patency Enhancement In The Emergency Department]] | ||
|- | |- | ||
| HAAMU-STENT | | [[HAAMU-STENT]] | ||
| [[Helsinki Area Acute Myocardial Infarction Treatment Re-Evaluation - Should The Patients Get A Drug-Eluting Or Normal Stent]] | | [[Helsinki Area Acute Myocardial Infarction Treatment Re-Evaluation - Should The Patients Get A Drug-Eluting Or Normal Stent]] | ||
|- | |- | ||
| HACA | | [[HACA]] | ||
| [[Mild Therapeuric Hypothermia To Improve The Neurologic Outcome After Cardiac Arrest]] | | [[Mild Therapeuric Hypothermia To Improve The Neurologic Outcome After Cardiac Arrest]] | ||
|- | |- | ||
| HAEST | | [[HAEST]] | ||
| [[Heparin In Acute Embolic Stroke Trial]] | | [[Heparin In Acute Embolic Stroke Trial]] | ||
|- | |- | ||
| HALT-C | | [[HALT-C]] | ||
| [[Hepatitis C Antiviral Long-Term Treatment To Prevent Cirrhosis ]] | | [[Hepatitis C Antiviral Long-Term Treatment To Prevent Cirrhosis ]] | ||
|- | |- | ||
| HALT-MI | | [[HALT-MI]] | ||
| [[Hu23F2G Anti-Adhesion To Limit Cytotoxic Injury Following Ami]] | | [[Hu23F2G Anti-Adhesion To Limit Cytotoxic Injury Following Ami]] | ||
|- | |- | ||
| HANDLS | | [[HANDLS]] | ||
| [[Health Aging In Nationally Diverse Longitudinal Samples]] | | [[Health Aging In Nationally Diverse Longitudinal Samples]] | ||
|- | |- | ||
| HANE | | [[HANE]] | ||
| [[Randomized, Double-Blind Multicenter Comparison Of Hydrochlorothiazide, Atenolol, Nitrendipine, And Enalapril In Antihypertensive Treatment]] | | [[Randomized, Double-Blind Multicenter Comparison Of Hydrochlorothiazide, Atenolol, Nitrendipine, And Enalapril In Antihypertensive Treatment]] | ||
|- | |- | ||
| HARDBALL | | [[HARDBALL]] | ||
| [[Heart Allograft Rejection: Detection With Breath Alkanes In Low Level]] | | [[Heart Allograft Rejection: Detection With Breath Alkanes In Low Level]] | ||
|- | |- | ||
| HARDBALL | | [[HARDBALL]] | ||
| [[Heart Allograft Rejection: Detection With Breath Alkanes In Low Levels]] | | [[Heart Allograft Rejection: Detection With Breath Alkanes In Low Levels]] | ||
|- | |- | ||
| HARP | | [[HARP]] | ||
| [[Harvard Atherosclerosis Reversibility Project]] | | [[Harvard Atherosclerosis Reversibility Project]] | ||
|- | |- | ||
| HART | | [[HART]] | ||
| [[Heparin-Aspirin Reperfusion Trial]] | | [[Heparin-Aspirin Reperfusion Trial]] | ||
|- | |- | ||
| HART II | | [[HART II]] | ||
| [[Randomized Comparison Of Enoxaparin, A Low-Molecular-Weight Heparin, With Unfractionated Heparin Adjunctive To Recombinant Tissue Plasminogen Activator Thrombolysis And Aspirin: Second Trial Of Heparin And Aspirin Reperfusion Therapy]] | | [[Randomized Comparison Of Enoxaparin, A Low-Molecular-Weight Heparin, With Unfractionated Heparin Adjunctive To Recombinant Tissue Plasminogen Activator Thrombolysis And Aspirin: Second Trial Of Heparin And Aspirin Reperfusion Therapy]] | ||
|- | |- | ||
| HAT | | [[HAT]] | ||
| [[Home Automatic External Defibrillator Trial]] | | [[Home Automatic External Defibrillator Trial]] | ||
|- | |- | ||
| HAT 1 | | [[HAT 1]] | ||
| [[Heparin-Associated Thrombocytopenia 1]] | | [[Heparin-Associated Thrombocytopenia 1]] | ||
|- | |- | ||
| HAT 2 | | [[HAT 2]] | ||
| [[Heparin-Associated Thrombocytopenia 2]] | | [[Heparin-Associated Thrombocytopenia 2]] | ||
|- | |- | ||
| HATS | | [[HATS]] | ||
| [[Hdl-Atherosclerosis Treatment Study]] | | [[Hdl-Atherosclerosis Treatment Study]] | ||
|- | |- | ||
| HDFP | | [[HDFP]] | ||
| [[Hypertension Detection And Follow-Up Program]] | | [[Hypertension Detection And Follow-Up Program]] | ||
|- | |- | ||
| HDOM | | [[HDOM]] | ||
| [[Heart Disease On The Mend]] | | [[Heart Disease On The Mend]] | ||
|- | |- | ||
| HeADDFIRST | | [[HeADDFIRST]] | ||
| [[Hemicraniectomy And Durotomy For Deterioration From Infarction Relating Swelling Trial]] | | [[Hemicraniectomy And Durotomy For Deterioration From Infarction Relating Swelling Trial]] | ||
|- | |- | ||
| HEART | | [[HEART]] | ||
| [[Healing And Early Afterload Reducing Therapy Trial]] | | [[Healing And Early Afterload Reducing Therapy Trial]] | ||
|- | |- | ||
| HEART | | [[HEART]] | ||
| [[Healing And Early Afterload Reducing Therapy]] | | [[Healing And Early Afterload Reducing Therapy]] | ||
|- | |- | ||
| HEAT 2 | | [[HEAT 2]] | ||
| [[Hypertension Endothelin Antagonist Treatment]] | | [[Hypertension Endothelin Antagonist Treatment]] | ||
|- | |- | ||
| Heidelberg | | [[Heidelberg]] | ||
| [[Heidelberg Trial]] | | [[Heidelberg Trial]] | ||
|- | |- | ||
| HELAS | | [[HELAS]] | ||
| [[Antithrombotic Therapy In Heart Failure: A Randomized Comparison Of Warfarin Vs. Aspirin]] | | [[Antithrombotic Therapy In Heart Failure: A Randomized Comparison Of Warfarin Vs. Aspirin]] | ||
|- | |- | ||
| HELAS | | [[HELAS]] | ||
| [[Antithrombotic Therapy In Heart Failure: A Randomized Comparison Of Warfarin Vs. Aspirin]] | | [[Antithrombotic Therapy In Heart Failure: A Randomized Comparison Of Warfarin Vs. Aspirin]] | ||
|- | |- | ||
| Helsinki Heart Study | | [[Helsinki Heart Study]] | ||
| [[Helsinski Heart Study]] | | [[Helsinski Heart Study]] | ||
|- | |- | ||
| Helsinki Heart Study | | [[Helsinki Heart Study]] | ||
| [[Helsinski Heart Study]] | | [[Helsinski Heart Study]] | ||
|- | |- | ||
| HEME | | [[HEME]] | ||
| [[Hemorrhage Early Mri Evaluation]] | | [[Hemorrhage Early Mri Evaluation]] | ||
|- | |- | ||
| HERO | | [[HERO]] | ||
| [[Hirulog Early Reperfusion/Occlusion Trial]] | | [[Hirulog Early Reperfusion/Occlusion Trial]] | ||
|- | |- | ||
| HERO | | [[HERO]] | ||
| [[Hirulog Early Reperfusion/Occlusion Trial]] | | [[Hirulog Early Reperfusion/Occlusion Trial]] | ||
|- | |- | ||
| HERO-2 | | [[HERO-2]] | ||
| [[Hirulog And Early Reperfusion Or Occlusion Trial]] | | [[Hirulog And Early Reperfusion Or Occlusion Trial]] | ||
|- | |- | ||
| HERS | | [[HERS]] | ||
| [[Heart And Estrogen/Progestin Replacement Study]] | | [[Heart And Estrogen/Progestin Replacement Study]] | ||
|- | |- | ||
| HERS | | [[HERS]] | ||
| [[Heart And Estrogen/Progestin Replacement Study Hiv Epidemiology Research Study]] | | [[Heart And Estrogen/Progestin Replacement Study Hiv Epidemiology Research Study]] | ||
|- | |- | ||
| HESTIA | | [[HESTIA]] | ||
| [[Home Evaluation Of Stroke Induced Aid]] | | [[Home Evaluation Of Stroke Induced Aid]] | ||
|- | |- | ||
| HF-ACTION | | [[HF-ACTION]] | ||
| [[Heart Failure–A Randomized Controlled Trial Investigating Outcomes Of Exercise Training]] | | [[Heart Failure–A Randomized Controlled Trial Investigating Outcomes Of Exercise Training]] | ||
|- | |- | ||
| HF-ACTION Substudy | | [[HF-ACTION Substudy]] | ||
| [[Effect Of Exercise Training On Health-Related Quality Of Life In Patients With Chronic Heart Failure]] | | [[Effect Of Exercise Training On Health-Related Quality Of Life In Patients With Chronic Heart Failure]] | ||
|- | |- | ||
| HHH | | [[HHH]] | ||
| [[Home Or Hospital Heart Failure]] | | [[Home Or Hospital Heart Failure]] | ||
|- | |- | ||
| HIJ-CREATE | | [[HIJ-CREATE]] | ||
| [[Heart Institute Of Japan Candesartan Randomized Trial For Evaluation In Coronary Artery Disease]] | | [[Heart Institute Of Japan Candesartan Randomized Trial For Evaluation In Coronary Artery Disease]] | ||
|- | |- | ||
| HIPS | | [[HIPS]] | ||
| [[Heparin Infusion Prior To Stenting ]] | | [[Heparin Infusion Prior To Stenting ]] | ||
|- | |- | ||
| HIT | | [[HIT]] | ||
| [[Hdl-Cholesterol Intervention Trial Hirudin For The Improvement Of Thrombolysis]] | | [[Hdl-Cholesterol Intervention Trial Hirudin For The Improvement Of Thrombolysis]] | ||
|- | |- | ||
| HIT-I | | [[HIT-I]] | ||
| [[Hirudin For The Improvement Of Thrombolysis]] | | [[Hirudin For The Improvement Of Thrombolysis]] | ||
|- | |- | ||
| HIT-III | | [[HIT-III]] | ||
| [[Hirudin For Improvement Of Thrombolysis]] | | [[Hirudin For Improvement Of Thrombolysis]] | ||
|- | |- | ||
| HOME | | [[HOME]] | ||
| [[Hyperinsulinemia: The Outcome Of Its Metabolic Effects]] | | [[Hyperinsulinemia: The Outcome Of Its Metabolic Effects]] | ||
|- | |- | ||
| HOPE | | [[HOPE]] | ||
| [[Heart Outcomes Prevention Evaluation ]] | | [[Heart Outcomes Prevention Evaluation ]] | ||
|- | |- | ||
| HOPE | | [[HOPE]] | ||
| [[The Heart Outcomes Prevention Evaluation Study]] | | [[The Heart Outcomes Prevention Evaluation Study]] | ||
|- | |- | ||
| HOPE-2 | | [[HOPE-2]] | ||
| [[Heart Outcomes Prevention Evaluation]] | | [[Heart Outcomes Prevention Evaluation]] | ||
|- | |- | ||
| HOPE-TOO | | [[HOPE-TOO]] | ||
| [[Heart Outcomes Prevention Evaluation - The Ongoing Outcomes ]] | | [[Heart Outcomes Prevention Evaluation - The Ongoing Outcomes ]] | ||
|- | |- | ||
| HORIZON | | [[HORIZON]] | ||
| [[Health Outcomes And Reduced Incidence With Zoledronic Once Yearly]] | | [[Health Outcomes And Reduced Incidence With Zoledronic Once Yearly]] | ||
|- | |- | ||
| HORIZONS-AMI | | [[HORIZONS-AMI]] | ||
| [[Harmonizing Outcomes With Revascularization And Stents In Acute Myocardial Infarction]] | | [[Harmonizing Outcomes With Revascularization And Stents In Acute Myocardial Infarction]] | ||
|- | |- | ||
| HORIZONS-AMI Stent | | [[HORIZONS-AMI Stent]] | ||
| [[Harmonizing Outcomes With Revascularization And Stents In Acute Myocardial Infarction]] | | [[Harmonizing Outcomes With Revascularization And Stents In Acute Myocardial Infarction]] | ||
|- | |- | ||
| HOS | | [[HOS]] | ||
| [[Hypertension-Obesity-Sibutramine]] | | [[Hypertension-Obesity-Sibutramine]] | ||
|- | |- | ||
| HOT | | [[HOT]] | ||
| [[Hypertension Optimal Treatment Study]] | | [[Hypertension Optimal Treatment Study]] | ||
|- | |- | ||
| HOT | | [[HOT]] | ||
| [[Hypertension Optimum Treatment]] | | [[Hypertension Optimum Treatment]] | ||
|- | |- | ||
| HPS | | [[HPS]] | ||
| [[Medical Research Council/British Heart Foundation Heart Protection Study]] | | [[Medical Research Council/British Heart Foundation Heart Protection Study]] | ||
|- | |- | ||
| HPS | | [[HPS]] | ||
| [[Heart Protection Study]] | | [[Heart Protection Study]] | ||
|- | |- | ||
| HRS | | [[HRS]] | ||
| [[Health And Retirement Study]] | | [[Health And Retirement Study]] | ||
|- | |- | ||
| Hy-C | | [[Hy-C]] | ||
| [[The Hydralazine Captopril Trial]] | | [[The Hydralazine Captopril Trial]] | ||
|- | |- | ||
| HYVET | | [[HYVET]] | ||
| [[Hypertension In The Very Elderly Trial]] | | [[Hypertension In The Very Elderly Trial]] | ||
|- | |- | ||
| HYVET | | [[HYVET]] | ||
| [[Hypertension In The Very Elderly Trial]] | | [[Hypertension In The Very Elderly Trial]] | ||
|- | |- | ||
| IBIS-2 | | [[IBIS-2]] | ||
| [[Integrated Biomarker And Imaging Study-2]] | | [[Integrated Biomarker And Imaging Study-2]] | ||
|- | |- | ||
| ICE-IT | | [[ICE-IT]] | ||
| [[Intravascular Cooling Adjunctive To Primary Coronary Intervention]] | | [[Intravascular Cooling Adjunctive To Primary Coronary Intervention]] | ||
|- | |- | ||
| ICON | | [[ICON]] | ||
| [[Ionic Versus Nonionic Contrast To Obviate Worsening Nephropathy After Angioplasty In Chronic Renal Failure Patients]] | | [[Ionic Versus Nonionic Contrast To Obviate Worsening Nephropathy After Angioplasty In Chronic Renal Failure Patients]] | ||
|- | |- | ||
| ICSS | | [[ICSS]] | ||
| [[International Carotid Stenting Study (Cavatas-2)]] | | [[International Carotid Stenting Study (Cavatas-2)]] | ||
|- | |- | ||
| ICTUS | | [[ICTUS]] | ||
| [[Invasive Versus Conservative Treatment In Unstable Coronary Syndromes]] | | [[Invasive Versus Conservative Treatment In Unstable Coronary Syndromes]] | ||
|- | |- | ||
| IDEAL | | [[IDEAL]] | ||
| [[Incremental Decrease In Clinical Endpoints Through Aggressive Lipid Lowering]] | | [[Incremental Decrease In Clinical Endpoints Through Aggressive Lipid Lowering]] | ||
|- | |- | ||
| IDEAL | | [[IDEAL]] | ||
| [[Incremental Decrease In Endpoints Through Aggressive Lipid Lowering Iressa Dose Evaluation In Advanced Lung Cancer]] | | [[Incremental Decrease In Endpoints Through Aggressive Lipid Lowering Iressa Dose Evaluation In Advanced Lung Cancer]] | ||
|- | |- | ||
| IDNT | | [[IDNT]] | ||
| [[Irbesartan Diabetic Nephropathy Trial]] | | [[Irbesartan Diabetic Nephropathy Trial]] | ||
|- | |- | ||
| IDNT | | [[IDNT]] | ||
| [[Irbesartan In Diabetic Nephropathy Trial]] | | [[Irbesartan In Diabetic Nephropathy Trial]] | ||
|- | |- | ||
| IHAST | | [[IHAST]] | ||
| [[Intraoperative Hypothermia For Aneurysm Surgery Trial]] | | [[Intraoperative Hypothermia For Aneurysm Surgery Trial]] | ||
|- | |- | ||
| ILLUMINATE | | [[ILLUMINATE]] | ||
| [[ Investigation Of Lipid Level Management To Understand Its Impact In Atherosclerotic Events]] | | [[ Investigation Of Lipid Level Management To Understand Its Impact In Atherosclerotic Events]] | ||
|- | |- | ||
| ILLUSTRATE | | [[ILLUSTRATE]] | ||
| [[Investigation Of Lipid Level Management Using Coronary Ultrasound To Assess Reduction Of Atherosclerosis By Cetp Inhibition And Hdl Elevation]] | | [[Investigation Of Lipid Level Management Using Coronary Ultrasound To Assess Reduction Of Atherosclerosis By Cetp Inhibition And Hdl Elevation]] | ||
|- | |- | ||
| IMAGES | | [[IMAGES]] | ||
| [[Intravenous Magnesium Efficacy In Stroke]] | | [[Intravenous Magnesium Efficacy In Stroke]] | ||
|- | |- | ||
| IMAGINE | | [[IMAGINE]] | ||
| [[Ischemia Management With Accupril Post-Bypass Graft Via Inhibition Of The Converting Enzyme]] | | [[Ischemia Management With Accupril Post-Bypass Graft Via Inhibition Of The Converting Enzyme]] | ||
|- | |- | ||
| IMAGINE | | [[IMAGINE]] | ||
| [[Ischemic Management With Accupril Post Bypass Graft Via Inhibition Of Converting Enzyme]] | | [[Ischemic Management With Accupril Post Bypass Graft Via Inhibition Of Converting Enzyme]] | ||
|- | |- | ||
| IMPACT | | [[IMPACT]] | ||
| [[Integrilin To Manage Platelet Aggregation To Prevent Coronary Thrombosis International Mexiletine Or Placebo Antiarrhythmic Coronary TrialInternational Multiple Sclerosis Secondary Progressive Avonex Controlled Trial]] | | [[Integrilin To Manage Platelet Aggregation To Prevent Coronary Thrombosis International Mexiletine Or Placebo Antiarrhythmic Coronary TrialInternational Multiple Sclerosis Secondary Progressive Avonex Controlled Trial]] | ||
|- | |- | ||
| IMPACT II | | [[IMPACT II]] | ||
| [[Integrilin To Minimise Platelet Aggregation And Coronary Thrombus - II]] | | [[Integrilin To Minimise Platelet Aggregation And Coronary Thrombus - II]] | ||
|- | |- | ||
| IMPACT-HF | | [[IMPACT-HF]] | ||
| [[Initiation Management Predischarge: Process For Assessment Of Carvedilol Therapy In Heart Failure]] | | [[Initiation Management Predischarge: Process For Assessment Of Carvedilol Therapy In Heart Failure]] | ||
|- | |- | ||
| IMPRESS | | [[IMPRESS]] | ||
| [[ Immunosuppressive Therapy For The Prevention Of Restenosis After Coronary Artery Stent Implantation]] | | [[ Immunosuppressive Therapy For The Prevention Of Restenosis After Coronary Artery Stent Implantation]] | ||
|- | |- | ||
| IMPRESS | | [[IMPRESS]] | ||
| [[Inhibition Of Metalloprotease By Bms-186716 In A Randomized Exercise And Symptoms Study ]] | | [[Inhibition Of Metalloprotease By Bms-186716 In A Randomized Exercise And Symptoms Study ]] | ||
|- | |- | ||
| IMPROVE-CHF | | [[IMPROVE-CHF]] | ||
| [[Improved Management Of Patients With Congestive Heart Failure]] | | [[Improved Management Of Patients With Congestive Heart Failure]] | ||
|- | |- | ||
| IMS | | [[IMS]] | ||
| [[Interventional Management Of Stroke Study]] | | [[Interventional Management Of Stroke Study]] | ||
|- | |- | ||
| IN-CHF | | [[IN-CHF]] | ||
| [[Italian Network - Congestive Heart Failure]] | | [[Italian Network - Congestive Heart Failure]] | ||
|- | |- | ||
| INCOMIN | | [[INCOMIN]] | ||
| [[Independent Comparison Of Interferon (Betaseron V. Avonex In Relapsing-Remitting Multiple Sclerosis (Rrms)]] | | [[Independent Comparison Of Interferon (Betaseron V. Avonex In Relapsing-Remitting Multiple Sclerosis (Rrms)]] | ||
|- | |- | ||
| InDDEx | | [[InDDEx]] | ||
| [[Investigation Into Delay To Diagnosis Of Alzheimer Disease With Exelon]] | | [[Investigation Into Delay To Diagnosis Of Alzheimer Disease With Exelon]] | ||
|- | |- | ||
| INHIBIT | | [[INHIBIT]] | ||
| [[Intimal Hyperplasia Inhibition With Beta In-Stent Trial]] | | [[Intimal Hyperplasia Inhibition With Beta In-Stent Trial]] | ||
|- | |- | ||
| INHIBIT | | [[INHIBIT]] | ||
| [[Intimal Hyperplasia Inhibition With Beta In-Stent Trial]] | | [[Intimal Hyperplasia Inhibition With Beta In-Stent Trial]] | ||
|- | |- | ||
| INJECT | | [[INJECT]] | ||
| [[International Joint Efficacy Comparison Of Thrombolytics]] | | [[International Joint Efficacy Comparison Of Thrombolytics]] | ||
|- | |- | ||
| INSIGHT | | [[INSIGHT]] | ||
| [[International Nifedipine Gits Study: Intervention As A Goal In Hypertension Treatment]] | | [[International Nifedipine Gits Study: Intervention As A Goal In Hypertension Treatment]] | ||
|- | |- | ||
| INSIGHT | | [[INSIGHT]] | ||
| [[International Nifedipine Once-Daily Study – Intervention As A Goal In Hypertension Treatment]] | | [[International Nifedipine Once-Daily Study – Intervention As A Goal In Hypertension Treatment]] | ||
|- | |- | ||
| INSPIRE | | [[INSPIRE]] | ||
| [[Adenosine Sestamibi Post-Infarction Evaluation (Inspire) Trial]] | | [[Adenosine Sestamibi Post-Infarction Evaluation (Inspire) Trial]] | ||
|- | |- | ||
| INSYNC | | [[INSYNC]] | ||
| [[Multisite Pacing As A Supplemental Treatment Of Congestive Heart Failure: The Medtronic Inc. Insync Study]] | | [[Multisite Pacing As A Supplemental Treatment Of Congestive Heart Failure: The Medtronic Inc. Insync Study]] | ||
|- | |- | ||
| INTACT | | [[INTACT]] | ||
| [[Iressa Non–Small Cell Lung Cancer Trial Assessing Combination Treatment]] | | [[Iressa Non–Small Cell Lung Cancer Trial Assessing Combination Treatment]] | ||
|- | |- | ||
| INTAMI | | [[INTAMI]] | ||
| [[Integrilin In Acute Myocardial Infarction]] | | [[Integrilin In Acute Myocardial Infarction]] | ||
|- | |- | ||
| INTEGRITI | | [[INTEGRITI]] | ||
| [[Integrilin And Tenecteplase In Acute Myocardial Infarction]] | | [[Integrilin And Tenecteplase In Acute Myocardial Infarction]] | ||
|- | |- | ||
| INTEGRITI | | [[INTEGRITI]] | ||
| [[Integrilin And Tenecteplase In Acute Myocardial Infarction ]] | | [[Integrilin And Tenecteplase In Acute Myocardial Infarction ]] | ||
|- | |- | ||
| INTERACT | | [[INTERACT]] | ||
| [[Integrilin And Enoxaparin Randomized Assessment Of Acute Coronary Syndrome Treatment]] | | [[Integrilin And Enoxaparin Randomized Assessment Of Acute Coronary Syndrome Treatment]] | ||
|- | |- | ||
| INTERCEPT | | [[INTERCEPT]] | ||
| [[Incomplete Infarction Trial Of European Research Collaborators Evaluating Prognosis Post-Thrombolysis (Diltiazem)]] | | [[Incomplete Infarction Trial Of European Research Collaborators Evaluating Prognosis Post-Thrombolysis (Diltiazem)]] | ||
|- | |- | ||
| INTERHEART | | [[INTERHEART]] | ||
| [[A Study Of Risk Factors For First Myocardial Infarction In 52 Countries And Over 27,000 Subjects]] | | [[A Study Of Risk Factors For First Myocardial Infarction In 52 Countries And Over 27,000 Subjects]] | ||
|- | |- | ||
| InTIME | | [[InTIME]] | ||
| [[Intravenous Npa For Treatment Of Infarcting Myocardium Early ]] | | [[Intravenous Npa For Treatment Of Infarcting Myocardium Early ]] | ||
|- | |- | ||
| InTime-2 | | [[InTime-2]] | ||
| [[Intravenous Npa For Treatment Of Infarcting Myocardium Early]] | | [[Intravenous Npa For Treatment Of Infarcting Myocardium Early]] | ||
|- | |- | ||
| INTrEPID | | [[INTrEPID]] | ||
| [[Investigation Of Non–Transplant-Eligible Patients Who Are Inotrope Dependent See ]] | | [[Investigation Of Non–Transplant-Eligible Patients Who Are Inotrope Dependent See ]] | ||
|- | |- | ||
| INTRINSIC RV | | [[INTRINSIC RV]] | ||
| [[ Inhibition Of Unnecessary Rv Pacing With Av Search Hysteresis In Icds]] | | [[ Inhibition Of Unnecessary Rv Pacing With Av Search Hysteresis In Icds]] | ||
|- | |- | ||
| INTRO-AMI | | [[INTRO-AMI]] | ||
| [[Integrilin And Reduced Dose Of Thrombolytic In Acute Myocardial Infarction]] | | [[Integrilin And Reduced Dose Of Thrombolytic In Acute Myocardial Infarction]] | ||
|- | |- | ||
| INVEST | | [[INVEST]] | ||
| [[International Verapamil-Trandolapril Study]] | | [[International Verapamil-Trandolapril Study]] | ||
|- | |- | ||
| IONA | | [[IONA]] | ||
| [[Effect Of Nicorandil On Coronary Events In Patients With Stable]] | | [[Effect Of Nicorandil On Coronary Events In Patients With Stable]] | ||
|- | |- | ||
| IONA | | [[IONA]] | ||
| [[Impact Of Nicorandil In Angina]] | | [[Impact Of Nicorandil In Angina]] | ||
|- | |- | ||
| IONDT | | [[IONDT]] | ||
| [[Ischemic Optic Neuropathy Decompression Trial]] | | [[Ischemic Optic Neuropathy Decompression Trial]] | ||
|- | |- | ||
| I-PRESERVE | | [[I-PRESERVE]] | ||
| [[Rbesartan In Heart Failure With Preserved Ejection Fraction Study]] | | [[Rbesartan In Heart Failure With Preserved Ejection Fraction Study]] | ||
|- | |- | ||
| IRAS | | [[IRAS]] | ||
| [[Insulin Resistance Atherosclerosis Study]] | | [[Insulin Resistance Atherosclerosis Study]] | ||
|- | |- | ||
| IRIS | | [[IRIS]] | ||
| [[Isostent For Restenosis Intervention Study]] | | [[Isostent For Restenosis Intervention Study]] | ||
|- | |- | ||
| IRIS | | [[IRIS]] | ||
| [[Isostent For Restenosis Intervention Study]] | | [[Isostent For Restenosis Intervention Study]] | ||
|- | |- | ||
| IRMA 2 | | [[IRMA 2]] | ||
| [[Irbesartan In Type 2 Diabetes With Microalbuminuria 2]] | | [[Irbesartan In Type 2 Diabetes With Microalbuminuria 2]] | ||
|- | |- | ||
| IRMA 2 | | [[IRMA 2]] | ||
| [[Irbesartan (Avapro) Microalbuminuria Type 2]] | | [[Irbesartan (Avapro) Microalbuminuria Type 2]] | ||
|- | |- | ||
| ISAAC | | [[ISAAC]] | ||
| [[International Study Of Asthma And Allergies In Childhood]] | | [[International Study Of Asthma And Allergies In Childhood]] | ||
|- | |- | ||
| ISAM | | [[ISAM]] | ||
| [[Intravenous Streptokinase In Acute Myocardial Infarction]] | | [[Intravenous Streptokinase In Acute Myocardial Infarction]] | ||
|- | |- | ||
| ISAR | | [[ISAR]] | ||
| [[Intracoronary Stenting And Antithrombotic Regimen Trial]] | | [[Intracoronary Stenting And Antithrombotic Regimen Trial]] | ||
|- | |- | ||
| ISAR | | [[ISAR]] | ||
| [[Individualizable Drug-Eluting Stent System To Abrogate Restenosis Project]] | | [[Individualizable Drug-Eluting Stent System To Abrogate Restenosis Project]] | ||
|- | |- | ||
| ISAR | | [[ISAR]] | ||
| [[Intracoronary Stenting And Antithrombotic Regimen]] | | [[Intracoronary Stenting And Antithrombotic Regimen]] | ||
|- | |- | ||
| ISAR DIABETES | | [[ISAR DIABETES]] | ||
| [[Paclitaxel-Eluting Stent Versus Sirolimus-Eluting Stent For The Prevention Of Restenosis In Diabetic Patients With Coronary Artery Disease]] | | [[Paclitaxel-Eluting Stent Versus Sirolimus-Eluting Stent For The Prevention Of Restenosis In Diabetic Patients With Coronary Artery Disease]] | ||
|- | |- | ||
| ISAR REACT | | [[ISAR REACT]] | ||
| [[Intracoronary Stenting And Antithrombotic Regimen Rapid Early Action For Coronary Treatment]] | | [[Intracoronary Stenting And Antithrombotic Regimen Rapid Early Action For Coronary Treatment]] | ||
|- | |- | ||
| ISAR-CHOICE | | [[ISAR-CHOICE]] | ||
| [[Intracoronary Stenting And Antithrombotic Regimen: Choose Between 3 High Oral Doses For Immediate Clopidogrel Effect]] | | [[Intracoronary Stenting And Antithrombotic Regimen: Choose Between 3 High Oral Doses For Immediate Clopidogrel Effect]] | ||
|- | |- | ||
| ISAR-COOL | | [[ISAR-COOL]] | ||
| [[Intracoronary Stenting With Antithrombotic Regimen Cooling-Off]] | | [[Intracoronary Stenting With Antithrombotic Regimen Cooling-Off]] | ||
|- | |- | ||
| ISAR-DESIRE | | [[ISAR-DESIRE]] | ||
| [[Drug-Eluting Stents For In-Stent Restenosis]] | | [[Drug-Eluting Stents For In-Stent Restenosis]] | ||
|- | |- | ||
| ISAR-LEFT MAIN | | [[ISAR-LEFT MAIN]] | ||
| [[Intracoronary Stenting And Angiographic Results: Drug-Eluting Stents For Unprotected Coronary Left Main Lesions]] | | [[Intracoronary Stenting And Angiographic Results: Drug-Eluting Stents For Unprotected Coronary Left Main Lesions]] | ||
|- | |- | ||
| ISAR-PEACE | | [[ISAR-PEACE]] | ||
| [[ Intracoronary Stenting And Angiographic Restenosis: Promote Endothelial Cells With Estradiol]] | | [[ Intracoronary Stenting And Angiographic Restenosis: Promote Endothelial Cells With Estradiol]] | ||
|- | |- | ||
| ISAR-REACT 2 | | [[ISAR-REACT 2]] | ||
| [[Intracoronary Stenting And Antithrombotic Regimen: Rapid Early Action For Coronary Treatment]] | | [[Intracoronary Stenting And Antithrombotic Regimen: Rapid Early Action For Coronary Treatment]] | ||
|- | |- | ||
| ISAR-REACT 3 | | [[ISAR-REACT 3]] | ||
| [[Bivalirudin Versus Unfractionated Heparin During Percutaneous Coronary Intervention]] | | [[Bivalirudin Versus Unfractionated Heparin During Percutaneous Coronary Intervention]] | ||
|- | |- | ||
| ISAR-SHOCK | | [[ISAR-SHOCK]] | ||
| [[Impella Lp2.5 Vs. Iabp In Cardiogenic Shock]] | | [[Impella Lp2.5 Vs. Iabp In Cardiogenic Shock]] | ||
|- | |- | ||
| ISAR-STEREO | | [[ISAR-STEREO]] | ||
| [[Intracoronary Stenting And Angiographic Results: Strut Thickness Effect On Restenosis Outcomes (Isar-Stereo) Trial]] | | [[Intracoronary Stenting And Angiographic Results: Strut Thickness Effect On Restenosis Outcomes (Isar-Stereo) Trial]] | ||
|- | |- | ||
| ISAR-STEREO | | [[ISAR-STEREO]] | ||
| [[Intracoronary Stenting And Angiographic Results - Strut Thickness Effect On Restenosis Outcome]] | | [[Intracoronary Stenting And Angiographic Results - Strut Thickness Effect On Restenosis Outcome]] | ||
|- | |- | ||
| ISAR-STEREO - 2 | | [[ISAR-STEREO - 2]] | ||
| [[Intracoronary Stenting And Angiographic Results - Strut Thicness Effect On Restenosis Outcome Trial - 2]] | | [[Intracoronary Stenting And Angiographic Results - Strut Thicness Effect On Restenosis Outcome Trial - 2]] | ||
|- | |- | ||
| ISAR-SWEET | | [[ISAR-SWEET]] | ||
| [[Is Abciximab A Superior Way To Eliminate Elevated Thrombotic Risk In Diabetics]] | | [[Is Abciximab A Superior Way To Eliminate Elevated Thrombotic Risk In Diabetics]] | ||
|- | |- | ||
| ISAR-TEST | | [[ISAR-TEST]] | ||
| [[Randomized Trial Of The Yukon Nonpolymer-Based Rapamycin-Coated Stent And The Polymer-Based Paclitaxel-Eluting Stent In Patients With Coronary Artery Disease]] | | [[Randomized Trial Of The Yukon Nonpolymer-Based Rapamycin-Coated Stent And The Polymer-Based Paclitaxel-Eluting Stent In Patients With Coronary Artery Disease]] | ||
|- | |- | ||
| ISAR-TEST-2 | | [[ISAR-TEST-2]] | ||
| [[Intracoronary Stenting And Angiographic Results–Test Efficacy Of 3 Limus-Eluting Stents]] | | [[Intracoronary Stenting And Angiographic Results–Test Efficacy Of 3 Limus-Eluting Stents]] | ||
|- | |- | ||
| ISAR-TEST-3 | | [[ISAR-TEST-3]] | ||
| [[Intracoronary Stenting And Angiographic Restenosis Investigators – Test Efficacy Of Rapamycin-Eluting Stents With Different Polymer Coating Strategies]] | | [[Intracoronary Stenting And Angiographic Restenosis Investigators – Test Efficacy Of Rapamycin-Eluting Stents With Different Polymer Coating Strategies]] | ||
|- | |- | ||
| ISAT | | [[ISAT]] | ||
| [[International Subarachnoid Aneurysm Trial]] | | [[International Subarachnoid Aneurysm Trial]] | ||
|- | |- | ||
| ISIS-1 | | [[ISIS-1]] | ||
| [[First International Study Of Infarct Survival]] | | [[First International Study Of Infarct Survival]] | ||
|- | |- | ||
| ISIS-2 | | [[ISIS-2]] | ||
| [[International Study Of Infarct Survival-2]] | | [[International Study Of Infarct Survival-2]] | ||
|- | |- | ||
| ISIS-3 | | [[ISIS-3]] | ||
| [[ International Study Of Infarct Survival-3]] | | [[ International Study Of Infarct Survival-3]] | ||
|- | |- | ||
| ISIS-4 | | [[ISIS-4]] | ||
| [[Fourth International Study Of Infarct Survival]] | | [[Fourth International Study Of Infarct Survival]] | ||
|- | |- | ||
| IST | | [[IST]] | ||
| [[The International Stroke Trial]] | | [[The International Stroke Trial]] | ||
|- | |- | ||
| ISTICH | | [[ISTICH]] | ||
| [[International Surgical Trial In Intracerebral Hemorrhage]] | | [[International Surgical Trial In Intracerebral Hemorrhage]] | ||
|- | |- | ||
| ITALICS | | [[ITALICS]] | ||
| [[Investigation By The Thoraxcenter On Antisense Dna Using Local Delivery And Ivus After Coronary Stenting]] | | [[Investigation By The Thoraxcenter On Antisense Dna Using Local Delivery And Ivus After Coronary Stenting]] | ||
|- | |- | ||
| ITT | | [[ITT]] | ||
| [[Intraventricular Thrombolysis Trial]] | | [[Intraventricular Thrombolysis Trial]] | ||
|- | |- | ||
| IVAT | | [[IVAT]] | ||
| [[Intermediate Sized Vessel Atherectomy Trial]] | | [[Intermediate Sized Vessel Atherectomy Trial]] | ||
|- | |- | ||
| JAMIS | | [[JAMIS]] | ||
| [[Effects Of Aspirin And Trapidil On Cardiovascular Events After Acute Myocardial Infarction]] | | [[Effects Of Aspirin And Trapidil On Cardiovascular Events After Acute Myocardial Infarction]] | ||
|- | |- | ||
| JELIS | | [[JELIS]] | ||
| [[Japan Epa Lipid Intervention Study]] | | [[Japan Epa Lipid Intervention Study]] | ||
|- | |- | ||
| JPAD | | [[JPAD]] | ||
| [[Japanese Primary Prevention Of Atherosclerosis With Aspirin For Diabetes]] | | [[Japanese Primary Prevention Of Atherosclerosis With Aspirin For Diabetes]] | ||
|- | |- | ||
| JSAP | | [[JSAP]] | ||
| [[Japanese Stable Angina Pectoris Study]] | | [[Japanese Stable Angina Pectoris Study]] | ||
|- | |- | ||
| JUMBO-TIMI 26 | | [[JUMBO-TIMI 26]] | ||
| [[Joint Utilisation Of Medications To Block Platelets Optimally]] | | [[Joint Utilisation Of Medications To Block Platelets Optimally]] | ||
|- | |- | ||
| JUPITER | | [[JUPITER]] | ||
| [[Justification For The Use Of Statins In Prevention: An Intervention Trial Evaluating Rosuvastatin]] | | [[Justification For The Use Of Statins In Prevention: An Intervention Trial Evaluating Rosuvastatin]] | ||
|- | |- | ||
| J-WIND | | [[J-WIND]] | ||
| [[Japan Working Groups Of Acute Myocardial Infarction For The Reduction Of Necrotic Damage By Atrial Natriuretic Peptide Or Nicorandil]] | | [[Japan Working Groups Of Acute Myocardial Infarction For The Reduction Of Necrotic Damage By Atrial Natriuretic Peptide Or Nicorandil]] | ||
|- | |- | ||
| KAT II | | [[KAT II]] | ||
| [[Kuopio Angiogenesis Trial]] | | [[Kuopio Angiogenesis Trial]] | ||
|- | |- | ||
| LACI | | [[LACI]] | ||
| [[Laser Angioplasty For Critical Ischemia ]] | | [[Laser Angioplasty For Critical Ischemia ]] | ||
|- | |- | ||
| LADIP | | [[LADIP]] | ||
| [[Loire-Ardèche-Drôme-Isère-Puy-De-Dôme]] | | [[Loire-Ardèche-Drôme-Isère-Puy-De-Dôme]] | ||
|- | |- | ||
| LAMP | | [[LAMP]] | ||
| [[Locally Advanced Multimodality Protoco]] | | [[Locally Advanced Multimodality Protoco]] | ||
|- | |- | ||
| LARS | | [[LARS]] | ||
| [[Laser Angioplasty In Restenosed Stents]] | | [[Laser Angioplasty In Restenosed Stents]] | ||
|- | |- | ||
| LATE | | [[LATE]] | ||
| [[Late Assessment Of Thrombolytic Efficacy Study]] | | [[Late Assessment Of Thrombolytic Efficacy Study]] | ||
|- | |- | ||
| LAVA | | [[LAVA]] | ||
| [[Prospective, Randomized, Multicenter Comparison Of Laser-Facilitated Balloon Angioplasty Versus Stand-Alone Balloon Angioplasty In Patients With Obstructive Coronary Artery Disease]] | | [[Prospective, Randomized, Multicenter Comparison Of Laser-Facilitated Balloon Angioplasty Versus Stand-Alone Balloon Angioplasty In Patients With Obstructive Coronary Artery Disease]] | ||
|- | |- | ||
| L-CAD | | [[L-CAD]] | ||
| [[Lipid-Coronary Artery Disease (Pravastatin)]] | | [[Lipid-Coronary Artery Disease (Pravastatin)]] | ||
|- | |- | ||
| LCAS | | [[LCAS]] | ||
| [[The Lipoprotein And Coronary Atherosclerosis Study (Lcas): Lipid And Metabolic Factors Related To Atheroma And Clinical Events]] | | [[The Lipoprotein And Coronary Atherosclerosis Study (Lcas): Lipid And Metabolic Factors Related To Atheroma And Clinical Events]] | ||
|- | |- | ||
| LEADER | | [[LEADER]] | ||
| [[ Lower Extremity Arterial Disease Event Reduction Trial]] | | [[ Lower Extremity Arterial Disease Event Reduction Trial]] | ||
|- | |- | ||
| LEADERS | | [[LEADERS]] | ||
| [[Limus Eluted From A Durable Vs Erodable Stent Coating]] | | [[Limus Eluted From A Durable Vs Erodable Stent Coating]] | ||
|- | |- | ||
| LHT | | [[LHT]] | ||
| [[Lifestyle Heart Trial]] | | [[Lifestyle Heart Trial]] | ||
|- | |- | ||
| LIDO | | [[LIDO]] | ||
| [[Levosimendan Infusion Versus Dobutamine]] | | [[Levosimendan Infusion Versus Dobutamine]] | ||
|- | |- | ||
| LIFE | | [[LIFE]] | ||
| [[Losartan Intervention For Endpoint Reduction In Hypertension (Life) Study]] | | [[Losartan Intervention For Endpoint Reduction In Hypertension (Life) Study]] | ||
|- | |- | ||
| LIMB | | [[LIMB]] | ||
| [[Limbs International Medical Buflomedil Trial]] | | [[Limbs International Medical Buflomedil Trial]] | ||
|- | |- | ||
| LIMIT AMI | | [[LIMIT AMI]] | ||
| [[Limitation Of Myocardial Infarction Following Thrombolysis In Acute]] | | [[Limitation Of Myocardial Infarction Following Thrombolysis In Acute]] | ||
|- | |- | ||
| LIMIT-2 | | [[LIMIT-2]] | ||
| [[Second Leicester Magnesium Intervention Trial]] | | [[Second Leicester Magnesium Intervention Trial]] | ||
|- | |- | ||
| LIPID | | [[LIPID]] | ||
| [[Long-Term Intervention With Pravastatin In Ischemic Disease Trial]] | | [[Long-Term Intervention With Pravastatin In Ischemic Disease Trial]] | ||
|- | |- | ||
| LIPS | | [[LIPS]] | ||
| [[Lescol Intervention Prevention Study]] | | [[Lescol Intervention Prevention Study]] | ||
|- | |- | ||
| LISA | | [[LISA]] | ||
| [[Lescol In Severe Atherosclerosis Trial]] | | [[Lescol In Severe Atherosclerosis Trial]] | ||
|- | |- | ||
| LOCAT | | [[LOCAT]] | ||
| [[Prevention Of The Angiographic Progression Of Coronary And Vein-Graft Atherosclerosis By Gemfibrozil After Coronary Bypass Surgery In Men With Low Levels Of Hdl Cholesterol]] | | [[Prevention Of The Angiographic Progression Of Coronary And Vein-Graft Atherosclerosis By Gemfibrozil After Coronary Bypass Surgery In Men With Low Levels Of Hdl Cholesterol]] | ||
|- | |- | ||
| LONG DES II | | [[LONG DES II]] | ||
| [[Randomized Comparison Of The Efficacy Of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent In The Treatment Of Long Native Coronary Lesions]] | | [[Randomized Comparison Of The Efficacy Of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent In The Treatment Of Long Native Coronary Lesions]] | ||
|- | |- | ||
| LONG-DES | | [[LONG-DES]] | ||
| [[Multicenter Prospective Nonrandomized Registry Study For Drug-Eluting Stents In Very Long Coronary Lesions (Cypher Vs Taxus)]] | | [[Multicenter Prospective Nonrandomized Registry Study For Drug-Eluting Stents In Very Long Coronary Lesions (Cypher Vs Taxus)]] | ||
|- | |- | ||
| LRC-CPPT | | [[LRC-CPPT]] | ||
| [[Lipid Research Clinics Coronary Primary Prevention Trial]] | | [[Lipid Research Clinics Coronary Primary Prevention Trial]] | ||
|- | |- | ||
| MACH-1 | | [[MACH-1]] | ||
| [[Mortality Assessment In Congestive Heart Failure Trial]] | | [[Mortality Assessment In Congestive Heart Failure Trial]] | ||
|- | |- | ||
| MADIT | | [[MADIT]] | ||
| [[Multicenter Automatic Defibrillator Implantation Trial]] | | [[Multicenter Automatic Defibrillator Implantation Trial]] | ||
|- | |- | ||
| MADIT-II | | [[MADIT-II]] | ||
| [[Multicenter Automatic Defibrillator Implantation Trial II]] | | [[Multicenter Automatic Defibrillator Implantation Trial II]] | ||
|- | |- | ||
| MAGIC | | [[MAGIC]] | ||
| [[Magnesium In Coronaries]] | | [[Magnesium In Coronaries]] | ||
|- | |- | ||
| MAGIC | | [[MAGIC]] | ||
| [[Myoblast Autologous Grafting In Ischemic Cardiomyopathy]] | | [[Myoblast Autologous Grafting In Ischemic Cardiomyopathy]] | ||
|- | |- | ||
| MAGIC – Presented at AHA 2006 | | [[MAGIC – Presented at AHA 2006]] | ||
| [[Myoblast Autologous Grafting In Ischemic Cardiomyopathy]] | | [[Myoblast Autologous Grafting In Ischemic Cardiomyopathy]] | ||
|- | |- | ||
| Male Health | | [[Male Health]] | ||
| [[ Male Health Professionals Study]] | | [[ Male Health Professionals Study]] | ||
|- | |- | ||
| MAPPET-3 | | [[MAPPET-3]] | ||
| [[ Management Strategies And Prognosis Of Pulmonary Embolism-3 Trial]] | | [[ Management Strategies And Prognosis Of Pulmonary Embolism-3 Trial]] | ||
|- | |- | ||
| MARS | | [[MARS]] | ||
| [[The Monitored Atherosclerosis Regression Study]] | | [[The Monitored Atherosclerosis Regression Study]] | ||
|- | |- | ||
| MASCOT | | [[MASCOT]] | ||
| [[Management Of Atrial Fibrillation Suppression In Af-Hf Comorbidity Therapy]] | | [[Management Of Atrial Fibrillation Suppression In Af-Hf Comorbidity Therapy]] | ||
|- | |- | ||
| MASS | | [[MASS]] | ||
| [[The Medicine, Angioplasty Or Surgery Study]] | | [[The Medicine, Angioplasty Or Surgery Study]] | ||
|- | |- | ||
| MASS | | [[MASS]] | ||
| [[The Multicenter Aneurysm Screening Study (Mass) Into The Effect Of Abdominal Aortic Aneurysm Screening On Mortality In Men: A Randomized Controlled Trial]] | | [[The Multicenter Aneurysm Screening Study (Mass) Into The Effect Of Abdominal Aortic Aneurysm Screening On Mortality In Men: A Randomized Controlled Trial]] | ||
|- | |- | ||
| MASS-II | | [[MASS-II]] | ||
| [[Second Medicine, Angioplasty, Or Surgery Study]] | | [[Second Medicine, Angioplasty, Or Surgery Study]] | ||
|- | |- | ||
| MAST-E | | [[MAST-E]] | ||
| [[Thrombolytic Therapy With Streptokinase In Acute Ischemic Stroke]] | | [[Thrombolytic Therapy With Streptokinase In Acute Ischemic Stroke]] | ||
|- | |- | ||
| MASTER | | [[MASTER]] | ||
| [[Microvolt T Wave Alternans Testing For Risk Stratification Of Post-Myocardial Infarction Patients]] | | [[Microvolt T Wave Alternans Testing For Risk Stratification Of Post-Myocardial Infarction Patients]] | ||
|- | |- | ||
| MATCH | | [[MATCH]] | ||
| [[Management Of Atherothrombosis With Clopidogrel In High-Risk Patients]] | | [[Management Of Atherothrombosis With Clopidogrel In High-Risk Patients]] | ||
|- | |- | ||
| MATE | | [[MATE]] | ||
| [[Medicine Versus Angiography In Thrombolytic Exclusion Trial]] | | [[Medicine Versus Angiography In Thrombolytic Exclusion Trial]] | ||
|- | |- | ||
| MATH | | [[MATH]] | ||
| [[Endocrine And Renal Effects Of Nifedipine Gastrointestinal Theraputic System In Patients With Essential Hypertension: Results Of A Multicenter Trial]] | | [[Endocrine And Renal Effects Of Nifedipine Gastrointestinal Theraputic System In Patients With Essential Hypertension: Results Of A Multicenter Trial]] | ||
|- | |- | ||
| Matisse | | [[Matisse]] | ||
| [[Subcutaneous Fondaparinux Versus Intravenous Unfractionated Heparin In The Initial Treatment Of Pulmonary Embolism]] | | [[Subcutaneous Fondaparinux Versus Intravenous Unfractionated Heparin In The Initial Treatment Of Pulmonary Embolism]] | ||
|- | |- | ||
| MATTIS | | [[MATTIS]] | ||
| [[Randomized Evaluation Of Anticoagulation Versus Antiplatelet Therapy After Coronary Stent Implantation In High-Risk Patients: The Multicenter Aspirin And Ticlopidine Trial After Intracoronary Stenting]] | | [[Randomized Evaluation Of Anticoagulation Versus Antiplatelet Therapy After Coronary Stent Implantation In High-Risk Patients: The Multicenter Aspirin And Ticlopidine Trial After Intracoronary Stenting]] | ||
|- | |- | ||
| MAVErIC II | | [[MAVErIC II]] | ||
| [[30-Day Results From A Prospective Registry Of Carotid Stenting With The Exponent Stent And Distal Protection With The Guardwire In High Risk Patients]] | | [[30-Day Results From A Prospective Registry Of Carotid Stenting With The Exponent Stent And Distal Protection With The Guardwire In High Risk Patients]] | ||
|- | |- | ||
| MaVS | | [[MaVS]] | ||
| [[Metoprolol After Vascular Surgery]] | | [[Metoprolol After Vascular Surgery]] | ||
|- | |- | ||
| MDC | | [[MDC]] | ||
| [[Metoprolol In Dilated Cardiomyopathy Trial]] | | [[Metoprolol In Dilated Cardiomyopathy Trial]] | ||
|- | |- | ||
| MDPIT | | [[MDPIT]] | ||
| [[The Multicenter Diltiazem Post Infarction Trial]] | | [[The Multicenter Diltiazem Post Infarction Trial]] | ||
|- | |- | ||
| MDRD | | [[MDRD]] | ||
| [[Modification Of Diet In Renal Disease Study]] | | [[Modification Of Diet In Renal Disease Study]] | ||
|- | |- | ||
| MEDAL Program | | [[MEDAL Program]] | ||
| [[Multinational Etoricoxib And Diclofenac Arthritis Long-Term Study Program]] | | [[Multinational Etoricoxib And Diclofenac Arthritis Long-Term Study Program]] | ||
|- | |- | ||
| MEDENOX | | [[MEDENOX]] | ||
| [[Prophylaxis In Medical Patients With Enoxaparin]] | | [[Prophylaxis In Medical Patients With Enoxaparin]] | ||
|- | |- | ||
| MEGA | | [[MEGA]] | ||
| [[Management Of Elevated Cholesterol In The Primary Prevention Group Of Adult Japanese]] | | [[Management Of Elevated Cholesterol In The Primary Prevention Group Of Adult Japanese]] | ||
|- | |- | ||
| MEND-CABG II | | [[MEND-CABG II]] | ||
| [[Mc-1 To Eliminate Necrosis And Damage In Coronary Artery Bypass Graft Surgery II — Presented At Scai-Acc I2 Summit/Acc 2008]] | | [[Mc-1 To Eliminate Necrosis And Damage In Coronary Artery Bypass Graft Surgery II — Presented At Scai-Acc I2 Summit/Acc 2008]] | ||
|- | |- | ||
| MERIT-HF | | [[MERIT-HF]] | ||
| [[Metoprolol Cr/Xl Randomized Intervention Trial In Congestive Heart Failure]] | | [[Metoprolol Cr/Xl Randomized Intervention Trial In Congestive Heart Failure]] | ||
|- | |- | ||
| MERLIN | | [[MERLIN]] | ||
| [[Middlesbrough Early Revascularization To Limit Infarction]] | | [[Middlesbrough Early Revascularization To Limit Infarction]] | ||
|- | |- | ||
| MERLIN-TIMI 36 | | [[MERLIN-TIMI 36]] | ||
| [[Metabolic Efficiency With Ranolazine For Less Ischemia In Nste-Acs]] | | [[Metabolic Efficiency With Ranolazine For Less Ischemia In Nste-Acs]] | ||
|- | |- | ||
| METAFER | | [[METAFER]] | ||
| [[Use Of Metoprolol To Maintain Sinus Rhythm After Conversion From Persistent Atrial Fibrillation]] | | [[Use Of Metoprolol To Maintain Sinus Rhythm After Conversion From Persistent Atrial Fibrillation]] | ||
|- | |- | ||
| METEOR | | [[METEOR]] | ||
| [[Measuring Effects On Intima-Media Thickness: An Evaluation Of Rosuvastatin]] | | [[Measuring Effects On Intima-Media Thickness: An Evaluation Of Rosuvastatin]] | ||
|- | |- | ||
| MEXIS | | [[MEXIS]] | ||
| [[The Effects Of B-Receptor Antagonists In Patients With Clinical Evidence Of Heart Failure After Myocardial Infarction: Double Blind Comparison Of Meto]] | | [[The Effects Of B-Receptor Antagonists In Patients With Clinical Evidence Of Heart Failure After Myocardial Infarction: Double Blind Comparison Of Meto]] | ||
|- | |- | ||
| M-HART | | [[M-HART]] | ||
| [[Montreal Heart Attack Readjustment Trial]] | | [[Montreal Heart Attack Readjustment Trial]] | ||
|- | |- | ||
| MHFT | | [[MHFT]] | ||
| [[Munich Mild Heart Failure Trial]] | | [[Munich Mild Heart Failure Trial]] | ||
|- | |- | ||
| MIAMI | | [[MIAMI]] | ||
| [[Metoprolol In Acute Myocardial Infarction]] | | [[Metoprolol In Acute Myocardial Infarction]] | ||
|- | |- | ||
| MICRO-HOPE | | [[MICRO-HOPE]] | ||
| [[Microalbuminuria, Cardiovascular, And Renal Outcomes - Heart Outcomes Prevention Evaluation]] | | [[Microalbuminuria, Cardiovascular, And Renal Outcomes - Heart Outcomes Prevention Evaluation]] | ||
|- | |- | ||
| MILIS | | [[MILIS]] | ||
| [[Multiple Center Investigation Of The Limit Of Infarction]] | | [[Multiple Center Investigation Of The Limit Of Infarction]] | ||
|- | |- | ||
| MINT | | [[MINT]] | ||
| [[A Multicenter, Randomized Study Of Argatroban Versus Heparin As Adjunct To Tissue Plasminogen Activator (Tpa) In Acute Myocardial Infarction: Myocardial Infarction With Novastan And Tpa (Mint) Study]] | | [[A Multicenter, Randomized Study Of Argatroban Versus Heparin As Adjunct To Tissue Plasminogen Activator (Tpa) In Acute Myocardial Infarction: Myocardial Infarction With Novastan And Tpa (Mint) Study]] | ||
|- | |- | ||
| MIRACL | | [[MIRACL]] | ||
| [[Effects Of Atorvastatin On Early Recurrent Ischemic Events In Acute Coronary Syndromes. The Miracl Study: A Randomized Controlled Trial]] | | [[Effects Of Atorvastatin On Early Recurrent Ischemic Events In Acute Coronary Syndromes. The Miracl Study: A Randomized Controlled Trial]] | ||
|- | |- | ||
| MIRACLE ICD | | [[MIRACLE ICD]] | ||
| [[Multicenter Insync Implantable Cardioversion Defibrillation Randomized Clinical Evaluation]] | | [[Multicenter Insync Implantable Cardioversion Defibrillation Randomized Clinical Evaluation]] | ||
|- | |- | ||
| MIST | | [[MIST]] | ||
| [[Migraine Intervention With Starflex Technology]] | | [[Migraine Intervention With Starflex Technology]] | ||
|- | |- | ||
| MITI I | | [[MITI I]] | ||
| [[Myocardial Infarction Triage And Intervention Project--Phase I]] | | [[Myocardial Infarction Triage And Intervention Project--Phase I]] | ||
|- | |- | ||
| MITI II | | [[MITI II]] | ||
| [[Myocardial Infarction Triage And Intervention Project--Phase I]] | | [[Myocardial Infarction Triage And Intervention Project--Phase I]] | ||
|- | |- | ||
| MITRA | | [[MITRA]] | ||
| [[Maximal Individual Therapy In Acute Myocardial Infarction]] | | [[Maximal Individual Therapy In Acute Myocardial Infarction]] | ||
|- | |- | ||
| MOMENTUM | | [[MOMENTUM]] | ||
| [[Multicenter Trial Of The Orqis Medical Cancion System For The Enhanced Treatment Of Heart Failure Unresponsive To Medical Therapy]] | | [[Multicenter Trial Of The Orqis Medical Cancion System For The Enhanced Treatment Of Heart Failure Unresponsive To Medical Therapy]] | ||
|- | |- | ||
| MONICA | | [[MONICA]] | ||
| [[Monitoring Trends And Determinants In Cardiovascular Disease]] | | [[Monitoring Trends And Determinants In Cardiovascular Disease]] | ||
|- | |- | ||
| MOST | | [[MOST]] | ||
| [[Mode Selection Trial (Most) In Sinus Node Dysfunction]] | | [[Mode Selection Trial (Most) In Sinus Node Dysfunction]] | ||
|- | |- | ||
| MOXCON | | [[MOXCON]] | ||
| [[Excess Mortality In Chf Patients Treated With Sr Moxonidine Leads To Study Termination: Results Of The Sr Moxonidine For Congestive Heart Failure Trial]] | | [[Excess Mortality In Chf Patients Treated With Sr Moxonidine Leads To Study Termination: Results Of The Sr Moxonidine For Congestive Heart Failure Trial]] | ||
|- | |- | ||
| M-PATHY | | [[M-PATHY]] | ||
| [[Multicenter Pacing Therapy]] | | [[Multicenter Pacing Therapy]] | ||
|- | |- | ||
| MPIP | | [[MPIP]] | ||
| [[Multicenter Post-Infarction Program]] | | [[Multicenter Post-Infarction Program]] | ||
|- | |- | ||
| MR PCI | | [[MR PCI]] | ||
| [[Multicenter Registry Of High-Risk Percutaneous Coronary Intervention And Adequate Platelet Inhibition]] | | [[Multicenter Registry Of High-Risk Percutaneous Coronary Intervention And Adequate Platelet Inhibition]] | ||
|- | |- | ||
| MRFIT | | [[MRFIT]] | ||
| [[Multiple Risk Factor Intervention Trial]] | | [[Multiple Risk Factor Intervention Trial]] | ||
|- | |- | ||
| MUSIC | | [[MUSIC]] | ||
| [[Multicenter Ultrasound Guided Stent Implantation In The Coronaries]] | | [[Multicenter Ultrasound Guided Stent Implantation In The Coronaries]] | ||
|- | |- | ||
| MUST-EECP | | [[MUST-EECP]] | ||
| [[Multicenter Enhanced External Counterpulsation]] | | [[Multicenter Enhanced External Counterpulsation]] | ||
|- | |- | ||
| MUSTIC | | [[MUSTIC]] | ||
| [[Multisite Stimulation In Cardiomyopathies Study]] | | [[Multisite Stimulation In Cardiomyopathies Study]] | ||
|- | |- | ||
| MUSTT | | [[MUSTT]] | ||
| [[Multicenter Unsustained Tachycardia Trial]] | | [[Multicenter Unsustained Tachycardia Trial]] | ||
|- | |- | ||
| MVP | | [[MVP]] | ||
| [[Multivitamins And Probucol Study]] | | [[Multivitamins And Probucol Study]] | ||
|- | |- | ||
| NAMIS | | [[NAMIS]] | ||
| [[Nifedipine Angina Myocardial Infarction Study]] | | [[Nifedipine Angina Myocardial Infarction Study]] | ||
|- | |- | ||
| NAPA | | [[NAPA]] | ||
| [[Nesiritide Administered Peri-Anesthesia In Patients Undergoing Cardiac Surgery]] | | [[Nesiritide Administered Peri-Anesthesia In Patients Undergoing Cardiac Surgery]] | ||
|- | |- | ||
| NAPLES II | | [[NAPLES II]] | ||
| [[Novel Approaches For Preventing Or Limiting Events II]] | | [[Novel Approaches For Preventing Or Limiting Events II]] | ||
|- | |- | ||
| NASCET | | [[NASCET]] | ||
| [[North American Symptomatic Carotid Endarterectomy Trial]] | | [[North American Symptomatic Carotid Endarterectomy Trial]] | ||
|- | |- | ||
| NEPHRIC | | [[NEPHRIC]] | ||
| [[Nephrotoxicity In High-Risk Patients Study Of Isoosmolar And Low-Osmolar Non-Ionic Contrast Media Study]] | | [[Nephrotoxicity In High-Risk Patients Study Of Isoosmolar And Low-Osmolar Non-Ionic Contrast Media Study]] | ||
|- | |- | ||
| NETWORK | | [[NETWORK]] | ||
| [[Clinical Outcome With Enalapril In Symptomatic Chronic Heart Failure: A Dose Comparison]] | | [[Clinical Outcome With Enalapril In Symptomatic Chronic Heart Failure: A Dose Comparison]] | ||
|- | |- | ||
| NHANES III | | [[NHANES III]] | ||
| [[Third National Health And Nutrition Examination Survey]] | | [[Third National Health And Nutrition Examination Survey]] | ||
|- | |- | ||
| NHLBI | | [[NHLBI]] | ||
| [[The National Heart, Lung And Blood Institute Type II Coronary Intervention Study]] | | [[The National Heart, Lung And Blood Institute Type II Coronary Intervention Study]] | ||
|- | |- | ||
| NHLBI Dynamic | | [[NHLBI Dynamic]] | ||
| [[Nhlbi Dynamic Registry Of Percutaneous Interventions: A Comparison To The 1985-86 Registry]] | | [[Nhlbi Dynamic Registry Of Percutaneous Interventions: A Comparison To The 1985-86 Registry]] | ||
|- | |- | ||
| NICE | | [[NICE]] | ||
| [[Nitrates In Congestive Heart Failure (Nice) Study]] | | [[Nitrates In Congestive Heart Failure (Nice) Study]] | ||
|- | |- | ||
| NICE-SUGAR | | [[NICE-SUGAR]] | ||
| [[Normoglycemia In Intensive Care Evaluation–Survival Using Glucose Algorithm Regulation]] | | [[Normoglycemia In Intensive Care Evaluation–Survival Using Glucose Algorithm Regulation]] | ||
|- | |- | ||
| NICOLE | | [[NICOLE]] | ||
| [[Nisoldipine For Coronary Artery Disease In Leuven]] | | [[Nisoldipine For Coronary Artery Disease In Leuven]] | ||
|- | |- | ||
| NICS-EH | | [[NICS-EH]] | ||
| [[National Intervention Cooperative Study In Elderly Hypertensives]] | | [[National Intervention Cooperative Study In Elderly Hypertensives]] | ||
|- | |- | ||
| NO-PAIN | | [[NO-PAIN]] | ||
| [[Nitric Oxide In Peripheral Arterial Insufficiency]] | | [[Nitric Oxide In Peripheral Arterial Insufficiency]] | ||
|- | |- | ||
| NORDIL | | [[NORDIL]] | ||
| [[Nordic Diltiazem Study]] | | [[Nordic Diltiazem Study]] | ||
|- | |- | ||
| NORVIT | | [[NORVIT]] | ||
| [[Norwegian Vitamin Trial]] | | [[Norwegian Vitamin Trial]] | ||
|- | |- | ||
| Norwegian Nifedipine | | [[Norwegian Nifedipine]] | ||
| [[Norwegian Nifedipine Multi-Center Trial]] | | [[Norwegian Nifedipine Multi-Center Trial]] | ||
|- | |- | ||
| NRMI-2 | | [[NRMI-2]] | ||
| [[National Registry Of Myocardial Infarction (Second Phase)]] | | [[National Registry Of Myocardial Infarction (Second Phase)]] | ||
|- | |- | ||
| NUT-2 | | [[NUT-2]] | ||
| [[Efficacy Assessment Of Meloxicam, A Preferential Cyclooxygenase-2 Inhibitor, In Acute Coronary Syndromes Without St-Segment Elevation. The Nonsteroidal Anti-Inflammatory Drugs In Unstable Angina Treatment-2 (Nut-2) Pilot Study]] | | [[Efficacy Assessment Of Meloxicam, A Preferential Cyclooxygenase-2 Inhibitor, In Acute Coronary Syndromes Without St-Segment Elevation. The Nonsteroidal Anti-Inflammatory Drugs In Unstable Angina Treatment-2 (Nut-2) Pilot Study]] | ||
|- | |- | ||
| OARS | | [[OARS]] | ||
| [[Optimal Atherectomy Restenosis Study]] | | [[Optimal Atherectomy Restenosis Study]] | ||
|- | |- | ||
| OASIS-1 | | [[OASIS-1]] | ||
| [[Organization To Assess Strategies For Ischemic Syndromes]] | | [[Organization To Assess Strategies For Ischemic Syndromes]] | ||
|- | |- | ||
| OASIS-2 | | [[OASIS-2]] | ||
| [[Effects Of Long-Term, Moderate-Intensity Oral Anticoagulation In Addition To Aspirin In Unstable Angina]] | | [[Effects Of Long-Term, Moderate-Intensity Oral Anticoagulation In Addition To Aspirin In Unstable Angina]] | ||
|- | |- | ||
| OASIS-6 | | [[OASIS-6]] | ||
| [[Organization For The Assessment Of Strategies For Ischemic Syndromes 6]] | | [[Organization For The Assessment Of Strategies For Ischemic Syndromes 6]] | ||
|- | |- | ||
| OASIS-6 – GIK | | [[OASIS-6 – GIK]] | ||
| [[Oasis-6 – Glucose-Insulin-Potassium]] | | [[Oasis-6 – Glucose-Insulin-Potassium]] | ||
|- | |- | ||
| OAT | | [[OAT]] | ||
| [[Occluded Artery Trial]] | | [[Occluded Artery Trial]] | ||
|- | |- | ||
| OCBAS | | [[OCBAS]] | ||
| [[Optimal Coronary Balloon Angioplasty With Provisional Stenting Vs. Stent Trial]] | | [[Optimal Coronary Balloon Angioplasty With Provisional Stenting Vs. Stent Trial]] | ||
|- | |- | ||
| OCLA | | [[OCLA]] | ||
| [[Omeprazole Clopidogrel Aspirin]] | | [[Omeprazole Clopidogrel Aspirin]] | ||
|- | |- | ||
| ODESSA | | [[ODESSA]] | ||
| [[Optical Coherence Tomography For Des Safety]] | | [[Optical Coherence Tomography For Des Safety]] | ||
|- | |- | ||
| ODIXa-DVT | | [[ODIXa-DVT]] | ||
| [[Oral Direct Factor Xa Inhibitor Bay 59-7939 In Patients With Acute Symptomatic Deep-Vein Thrombosis]] | | [[Oral Direct Factor Xa Inhibitor Bay 59-7939 In Patients With Acute Symptomatic Deep-Vein Thrombosis]] | ||
|- | |- | ||
| ODIXa-HIP | | [[ODIXa-HIP]] | ||
| [[Oral, Direct Factor Xa Inhibitor, Bay 59-7939, Given Once Daily In Patients Undergoing Total Hip Replacement]] | | [[Oral, Direct Factor Xa Inhibitor, Bay 59-7939, Given Once Daily In Patients Undergoing Total Hip Replacement]] | ||
|- | |- | ||
| OMEGA | | [[OMEGA]] | ||
| [[Randomized Trial Of Omega-3 Fatty Acids On Top Of Modern Therapy After Acute Myocardial Infarction]] | | [[Randomized Trial Of Omega-3 Fatty Acids On Top Of Modern Therapy After Acute Myocardial Infarction]] | ||
|- | |- | ||
| ONTARGET | | [[ONTARGET]] | ||
| [[Ongoing Telmisartan Alone And In Combination With Ramipril Global Endpoint Trial]] | | [[Ongoing Telmisartan Alone And In Combination With Ramipril Global Endpoint Trial]] | ||
|- | |- | ||
| ON-TIME | | [[ON-TIME]] | ||
| [[Ongoing Tirofiban In Myocardial Infarction Evaluation Trial]] | | [[Ongoing Tirofiban In Myocardial Infarction Evaluation Trial]] | ||
|- | |- | ||
| On-TIME 2 | | [[On-TIME 2]] | ||
| [[Ongoing Tirofiban In Myocardial Infarction Evaluation 2 Trial]] | | [[Ongoing Tirofiban In Myocardial Infarction Evaluation 2 Trial]] | ||
|- | |- | ||
| OPALS | | [[OPALS]] | ||
| [[Ontario Prehospital Advanced Life Support]] | | [[Ontario Prehospital Advanced Life Support]] | ||
|- | |- | ||
| OPT-CHF | | [[OPT-CHF]] | ||
| [[Oxypurinol Compared With Placebo For Class III-Iv Nyha Congestive Heart Failure]] | | [[Oxypurinol Compared With Placebo For Class III-Iv Nyha Congestive Heart Failure]] | ||
|- | |- | ||
| OPTIC | | [[OPTIC]] | ||
| [[Optimal Pharmacological Therapy In Cardioverter Defibrillator Patients Trial]] | | [[Optimal Pharmacological Therapy In Cardioverter Defibrillator Patients Trial]] | ||
|- | |- | ||
| OPTIMAAL | | [[OPTIMAAL]] | ||
| [[Effects Of Losartan And Captopril On Mortality And Morbidity In High-Risk Patients After Acute Myocardial Infarction]] | | [[Effects Of Losartan And Captopril On Mortality And Morbidity In High-Risk Patients After Acute Myocardial Infarction]] | ||
|- | |- | ||
| OPTIME-CHF | | [[OPTIME-CHF]] | ||
| [[Outcomes Of A Prospective Trial Of Intravenous Milrinone For Exacerbations Of Chronic Heart Failure]] | | [[Outcomes Of A Prospective Trial Of Intravenous Milrinone For Exacerbations Of Chronic Heart Failure]] | ||
|- | |- | ||
| OPTIMIZE | | [[OPTIMIZE]] | ||
| [[Effect Of Image Optimization With Contrast On The Diagnostic Accuracy Of Dobutamine Echocardiography In Coronary Artery Disease]] | | [[Effect Of Image Optimization With Contrast On The Diagnostic Accuracy Of Dobutamine Echocardiography In Coronary Artery Disease]] | ||
|- | |- | ||
| OPUS | | [[OPUS]] | ||
| [[Optimal Angioplasty Versus Primary Stenting]] | | [[Optimal Angioplasty Versus Primary Stenting]] | ||
|- | |- | ||
| ORAR II | | [[ORAR II]] | ||
| [[Oral Treatment Of Restenosis]] | | [[Oral Treatment Of Restenosis]] | ||
|- | |- | ||
| ORBIT | | [[ORBIT]] | ||
| [[Oral Glycoprotein IIb/IIia Receptor Blockade To Inhibit Thrombosis]] | | [[Oral Glycoprotein IIb/IIia Receptor Blockade To Inhibit Thrombosis]] | ||
|- | |- | ||
| OSIRIS | | [[OSIRIS]] | ||
| [[Oral Sirolimus To Inhibit Recurrent In-Stent Stenosis]] | | [[Oral Sirolimus To Inhibit Recurrent In-Stent Stenosis]] | ||
|- | |- | ||
| OVERTURE | | [[OVERTURE]] | ||
| [[Omapatrilat Versus Enalapril Randomized Trial Of Utility In Reducing Events]] | | [[Omapatrilat Versus Enalapril Randomized Trial Of Utility In Reducing Events]] | ||
|- | |- | ||
| PABA CHF | | [[PABA CHF]] | ||
| [[Pulmonary Vein Antrum Isolation Vs. Av Node Ablation With Biventricular Pacing For Treatment Of Atrial Fibrillation In Patients With Congestive Heart Failure]] | | [[Pulmonary Vein Antrum Isolation Vs. Av Node Ablation With Biventricular Pacing For Treatment Of Atrial Fibrillation In Patients With Congestive Heart Failure]] | ||
|- | |- | ||
| PACCOCATH ISR | | [[PACCOCATH ISR]] | ||
| [[Treatment Of In-Stent Restenosis By Paclitaxel Coated Ptca Balloons]] | | [[Treatment Of In-Stent Restenosis By Paclitaxel Coated Ptca Balloons]] | ||
|- | |- | ||
| PACE | | [[PACE]] | ||
| [[Prevention By Low Dose Aspirin Of Cardiovascular Disease In The Elderly]] | | [[Prevention By Low Dose Aspirin Of Cardiovascular Disease In The Elderly]] | ||
|- | |- | ||
| PACIFIC | | [[PACIFIC]] | ||
| [[Percutaneous Transmyocardial Laser Revascularization For Severe Angina: The Pacific Randomized Trial]] | | [[Percutaneous Transmyocardial Laser Revascularization For Severe Angina: The Pacific Randomized Trial]] | ||
|- | |- | ||
| PACT | | [[PACT]] | ||
| [[Plasminogen Activator-Angioplasty Compatibility Trial]] | | [[Plasminogen Activator-Angioplasty Compatibility Trial]] | ||
|- | |- | ||
| PACT (Pravastatin) | | [[PACT (Pravastatin)]] | ||
| [[Pravastatin In Acute Coronary Treatment]] | | [[Pravastatin In Acute Coronary Treatment]] | ||
|- | |- | ||
| PAD | | [[PAD]] | ||
| [[Public Access Defibrillation Trial]] | | [[Public Access Defibrillation Trial]] | ||
|- | |- | ||
| PAMI | | [[PAMI]] | ||
| [[The Primary Angioplasty In Myocardial Infarction Study]] | | [[The Primary Angioplasty In Myocardial Infarction Study]] | ||
|- | |- | ||
| PAMI-stent | | [[PAMI-stent]] | ||
| [[The Primary Angioplasty In Myocardial Infarction Study]] | | [[The Primary Angioplasty In Myocardial Infarction Study]] | ||
|- | |- | ||
| PAPABEAR | | [[PAPABEAR]] | ||
| [[Prophylactic Amiodarone For The Prevention Of Arrhythmias That Begin Early After Revascularization, Valvular Repair Or Replacement]] | | [[Prophylactic Amiodarone For The Prevention Of Arrhythmias That Begin Early After Revascularization, Valvular Repair Or Replacement]] | ||
|- | |- | ||
| PARAGON | | [[PARAGON]] | ||
| [[Delaying And Preventing Ischemic Events In Patient With Acute Coronary Syndromes Using The Platelet Gp IIb/IIia Inhibitor Lamifiban]] | | [[Delaying And Preventing Ischemic Events In Patient With Acute Coronary Syndromes Using The Platelet Gp IIb/IIia Inhibitor Lamifiban]] | ||
|- | |- | ||
| PARAGON B | | [[PARAGON B]] | ||
| [[Platelet IIb/IIia Antagonist For The Reduction Of Acute Coronary Syndrome Events In A Global Organization Network]] | | [[Platelet IIb/IIia Antagonist For The Reduction Of Acute Coronary Syndrome Events In A Global Organization Network]] | ||
|- | |- | ||
| PARIS | | [[PARIS]] | ||
| [[Effect Of Ace Inhibitors On Angiographic Restenosis After Coronary Stenting (Paris): A Randomised, Double-Blind, Placebo-Controlled Trial]] | | [[Effect Of Ace Inhibitors On Angiographic Restenosis After Coronary Stenting (Paris): A Randomised, Double-Blind, Placebo-Controlled Trial]] | ||
|- | |- | ||
| PASE | | [[PASE]] | ||
| [[Pacemaker Selection In The Elderly]] | | [[Pacemaker Selection In The Elderly]] | ||
|- | |- | ||
| PASE(QOL) | | [[PASE(QOL)]] | ||
| [[Quality Of Life And Clinical Outcomes In Elderly Patients Treated With Ventricular Pacing As Compared With Dual-Chamber Pacing]] | | [[Quality Of Life And Clinical Outcomes In Elderly Patients Treated With Ventricular Pacing As Compared With Dual-Chamber Pacing]] | ||
|- | |- | ||
| PASSION | | [[PASSION]] | ||
| [[Paclitaxel Eluting Stent Versus Conventional Stent In St-Segment Elevation Myocardial Infarction]] | | [[Paclitaxel Eluting Stent Versus Conventional Stent In St-Segment Elevation Myocardial Infarction]] | ||
|- | |- | ||
| PATAF | | [[PATAF]] | ||
| [[Primary Prevention Of Arterial Thromboembolism In Non-Rheumatic Atrial Fibrillation In Primary Care: Randomised Controlled Trial Comparing Two Intensities Of Coumarin With Aspirin]] | | [[Primary Prevention Of Arterial Thromboembolism In Non-Rheumatic Atrial Fibrillation In Primary Care: Randomised Controlled Trial Comparing Two Intensities Of Coumarin With Aspirin]] | ||
|- | |- | ||
| PATCH | | [[PATCH]] | ||
| [[Program To Assess Alternative Treatment Strategies To Achieve Cardiac Health]] | | [[Program To Assess Alternative Treatment Strategies To Achieve Cardiac Health]] | ||
|- | |- | ||
| PATH-CHF | | [[PATH-CHF]] | ||
| [[The Pacing Therapies For Congestive Heart Failure (Path-Chf) Study]] | | [[The Pacing Therapies For Congestive Heart Failure (Path-Chf) Study]] | ||
|- | |- | ||
| PAVE | | [[PAVE]] | ||
| [[Biventricular Pacing After Ablate Compared With Right Ventricular Therapy]] | | [[Biventricular Pacing After Ablate Compared With Right Ventricular Therapy]] | ||
|- | |- | ||
| PCI CLARITY | | [[PCI CLARITY]] | ||
| [[Clopidogrel As Adjunctive Reperfusion Therapy: Percutaneous Coronary Intervention Subgroup Study]] | | [[Clopidogrel As Adjunctive Reperfusion Therapy: Percutaneous Coronary Intervention Subgroup Study]] | ||
|- | |- | ||
| PCI-CURE | | [[PCI-CURE]] | ||
| [[Effects Of Pretreatment With Clopidogrel And Aspirin Followed By Long-Term Therapy In Patients Undergoing Percutaneous Coronary Intervention: The Pci-Cure Study]] | | [[Effects Of Pretreatment With Clopidogrel And Aspirin Followed By Long-Term Therapy In Patients Undergoing Percutaneous Coronary Intervention: The Pci-Cure Study]] | ||
|- | |- | ||
| PCI-ExTRACT-TIMI 25 | | [[PCI-ExTRACT-TIMI 25]] | ||
| [[Percutaneous Coronary Intervention Among Patients Treated With Enoxaparin Versus Unfractionated Heparin Following Fibrinolytic Administration For St-Elevation Mi]] | | [[Percutaneous Coronary Intervention Among Patients Treated With Enoxaparin Versus Unfractionated Heparin Following Fibrinolytic Administration For St-Elevation Mi]] | ||
|- | |- | ||
| PC-Trial | | [[PC-Trial]] | ||
| [[Physical Counterpressure Manoeuvre Trial]] | | [[Physical Counterpressure Manoeuvre Trial]] | ||
|- | |- | ||
| PEACE | | [[PEACE]] | ||
| [[Platelet Activity Extinction In Non–Q-Wave Myocardial Infarction With Aspirin, Clopidogrel, And Eptifibatide]] | | [[Platelet Activity Extinction In Non–Q-Wave Myocardial Infarction With Aspirin, Clopidogrel, And Eptifibatide]] | ||
|- | |- | ||
| PEACE | | [[PEACE]] | ||
| [[Prevention Of Events With Angiotensin-Converting Enzyme Inhibition Trial]] | | [[Prevention Of Events With Angiotensin-Converting Enzyme Inhibition Trial]] | ||
|- | |- | ||
| PEECH | | [[PEECH]] | ||
| [[Prospective Evaluation Of Enhanced External Counterpulsation In Congestive Heart Failure]] | | [[Prospective Evaluation Of Enhanced External Counterpulsation In Congestive Heart Failure]] | ||
|- | |- | ||
| PENTUA | | [[PENTUA]] | ||
| [[Pentasaccharide In Unstable Angina]] | | [[Pentasaccharide In Unstable Angina]] | ||
|- | |- | ||
| PEP | | [[PEP]] | ||
| [[Pulmonary Embolism Prevention Trial]] | | [[Pulmonary Embolism Prevention Trial]] | ||
|- | |- | ||
| PEPAF | | [[PEPAF]] | ||
| [[Experimental Program For Physical Activity Promotion]] | | [[Experimental Program For Physical Activity Promotion]] | ||
|- | |- | ||
| PEP-CHF | | [[PEP-CHF]] | ||
| [[Perindopril For Elderly People With Chronic Heart Failure]] | | [[Perindopril For Elderly People With Chronic Heart Failure]] | ||
|- | |- | ||
| PEPI | | [[PEPI]] | ||
| [[Postmenopausal Estrogen/Progestin Interventions]] | | [[Postmenopausal Estrogen/Progestin Interventions]] | ||
|- | |- | ||
| PERISCOPE | | [[PERISCOPE]] | ||
| [[Pioglitazone Effect On Regression Of Intravascular Sonographic Coronary Obstruction Prospective Evaluation]] | | [[Pioglitazone Effect On Regression Of Intravascular Sonographic Coronary Obstruction Prospective Evaluation]] | ||
|- | |- | ||
| PERM | | [[PERM]] | ||
| [[Prospective Evaluation Of Reperfusion Markers]] | | [[Prospective Evaluation Of Reperfusion Markers]] | ||
|- | |- | ||
| PERSUADE | | [[PERSUADE]] | ||
| [[Perindopril Substudy In Coronary Artery Disease And Diabetes: The Diabetic Substudy Of Europa]] | | [[Perindopril Substudy In Coronary Artery Disease And Diabetes: The Diabetic Substudy Of Europa]] | ||
|- | |- | ||
| Perth | | [[Perth]] | ||
| [[Perth Community Stroke Study]] | | [[Perth Community Stroke Study]] | ||
|- | |- | ||
| PERTINENT | | [[PERTINENT]] | ||
| [[Perindopril, Thrombosis, Inflammation, Endothelial Dysfunction, And Neurohormonal Activation Trial, A Subanalysis Of Europa]] | | [[Perindopril, Thrombosis, Inflammation, Endothelial Dysfunction, And Neurohormonal Activation Trial, A Subanalysis Of Europa]] | ||
|- | |- | ||
| PHS II | | [[PHS II]] | ||
| [[Physicians' Health Study II]] | | [[Physicians' Health Study II]] | ||
|- | |- | ||
| PIAF | | [[PIAF]] | ||
| [[Rhythm Or Rate Control In Atrial Fibrillation-Pharmacological Intervention In Atrial Fibrillation (Piaf): A Randomised Trial]] | | [[Rhythm Or Rate Control In Atrial Fibrillation-Pharmacological Intervention In Atrial Fibrillation (Piaf): A Randomised Trial]] | ||
|- | |- | ||
| PICTURE | | [[PICTURE]] | ||
| [[Post-Intracoronary Treatment Ultrasound Result Evaluation]] | | [[Post-Intracoronary Treatment Ultrasound Result Evaluation]] | ||
|- | |- | ||
| PIHRATE | | [[PIHRATE]] | ||
| [[Polish-Italian-Hungarian Randomized Thrombectomy Trial]] | | [[Polish-Italian-Hungarian Randomized Thrombectomy Trial]] | ||
|- | |- | ||
| PIONEER | | [[PIONEER]] | ||
| [[Proactive, Prospective Pioglitazone Clinical Trial In Macrovascular Events]] | | [[Proactive, Prospective Pioglitazone Clinical Trial In Macrovascular Events]] | ||
|- | |- | ||
| PIOPED | | [[PIOPED]] | ||
| [[Prospective Investigation Of Pulmonary Embolism Diagnosis Study]] | | [[Prospective Investigation Of Pulmonary Embolism Diagnosis Study]] | ||
|- | |- | ||
| PLAC-II | | [[PLAC-II]] | ||
| [[Pravastatin, Lipids, And Atherosclerosis In The Carotid Arteries II]] | | [[Pravastatin, Lipids, And Atherosclerosis In The Carotid Arteries II]] | ||
|- | |- | ||
| PLASMA | | [[PLASMA]] | ||
| [[Phospholipase Levels And Serological Markers Of Atherosclerosis]] | | [[Phospholipase Levels And Serological Markers Of Atherosclerosis]] | ||
|- | |- | ||
| POISE | | [[POISE]] | ||
| [[Perioperative Ischemic Evaluation]] | | [[Perioperative Ischemic Evaluation]] | ||
|- | |- | ||
| POSCH | | [[POSCH]] | ||
| [[Program On The Surgical Control Of The Hyperlipidemias]] | | [[Program On The Surgical Control Of The Hyperlipidemias]] | ||
|- | |- | ||
| POST | | [[POST]] | ||
| [[Prevention Of Syncope Trial]] | | [[Prevention Of Syncope Trial]] | ||
|- | |- | ||
| Post CABG | | [[Post CABG]] | ||
| [[Post Coronary Artery Bypass Graft Trial]] | | [[Post Coronary Artery Bypass Graft Trial]] | ||
|- | |- | ||
| POZNAN | | [[POZNAN]] | ||
| [[Percutaneous Transvenous Transplantation Of Autologous Myoblasts In The Treatment Of Postinfarction Heart Failure]] | | [[Percutaneous Transvenous Transplantation Of Autologous Myoblasts In The Treatment Of Postinfarction Heart Failure]] | ||
|- | |- | ||
| PPAR Study | | [[PPAR Study]] | ||
| [[Peroxisome Proliferator–Activated Receptor Study]] | | [[Peroxisome Proliferator–Activated Receptor Study]] | ||
|- | |- | ||
| PPP | | [[PPP]] | ||
| [[Primary Prevention Project]] | | [[Primary Prevention Project]] | ||
|- | |- | ||
| PQRST | | [[PQRST]] | ||
| [[Probucol Quantitative Regression Swedish Trial]] | | [[Probucol Quantitative Regression Swedish Trial]] | ||
|- | |- | ||
| PRACTICAL | | [[PRACTICAL]] | ||
| [[Comparison Of Enalapril Versus Captopril On Left Ventricular Function And Survival Three Months After Acute Myocardial Infarction]] | | [[Comparison Of Enalapril Versus Captopril On Left Ventricular Function And Survival Three Months After Acute Myocardial Infarction]] | ||
|- | |- | ||
| PRAGUE | | [[PRAGUE]] | ||
| [[Primary Angioplasty In Patients Transferred From General Community Hospitals To Specialized Ptca Units With Or Without Emergency Thrombolysis]] | | [[Primary Angioplasty In Patients Transferred From General Community Hospitals To Specialized Ptca Units With Or Without Emergency Thrombolysis]] | ||
|- | |- | ||
| PRAGUE-8 | | [[PRAGUE-8]] | ||
| [[Primary Angioplasty In Patients Transferred From General Community Hospitals To Specialized Ptca Units With Or Without Emergency Thrombolysis-8]] | | [[Primary Angioplasty In Patients Transferred From General Community Hospitals To Specialized Ptca Units With Or Without Emergency Thrombolysis-8]] | ||
|- | |- | ||
| PRAISE | | [[PRAISE]] | ||
| [[Prospective Randomized Amlopidine Survival Evaluation]] | | [[Prospective Randomized Amlopidine Survival Evaluation]] | ||
|- | |- | ||
| PRAISE-1 | | [[PRAISE-1]] | ||
| [[Prospective Randomized Amlodipine Survival Evaluation-1]] | | [[Prospective Randomized Amlodipine Survival Evaluation-1]] | ||
|- | |- | ||
| PRAISE-2 | | [[PRAISE-2]] | ||
| [[Prospective Randomized Amlodipine Survival Evaluation-2]] | | [[Prospective Randomized Amlodipine Survival Evaluation-2]] | ||
|- | |- | ||
| PREAMI | | [[PREAMI]] | ||
| [[Perindopril Remodeling In Elderly With Acute Myocardial Infarction]] | | [[Perindopril Remodeling In Elderly With Acute Myocardial Infarction]] | ||
|- | |- | ||
| PRECISE | | [[PRECISE]] | ||
| [[Double-Blind, Placebo-Controlled Study Of The Effects Of Carvedilol In Patients With Moderate To Severe Heart Failure]] | | [[Double-Blind, Placebo-Controlled Study Of The Effects Of Carvedilol In Patients With Moderate To Severe Heart Failure]] | ||
|- | |- | ||
| PREDICT | | [[PREDICT]] | ||
| [[Effect Of Pravastatin On Angiographic Restenosis After Coronary Balloon Angioplasty]] | | [[Effect Of Pravastatin On Angiographic Restenosis After Coronary Balloon Angioplasty]] | ||
|- | |- | ||
| PREMIAR | | [[PREMIAR]] | ||
| [[Protection From Distal Embolization In High-Risk Patients With Acute St-Segment Elevation Myocardial Infarction]] | | [[Protection From Distal Embolization In High-Risk Patients With Acute St-Segment Elevation Myocardial Infarction]] | ||
|- | |- | ||
| PREMIER | | [[PREMIER]] | ||
| [[Effects Of Pg-116800, A Matrix Metalloproteinase Inhibitor, To Prevent Left Ventricular Remodeling After Acute Myocardial Infarction]] | | [[Effects Of Pg-116800, A Matrix Metalloproteinase Inhibitor, To Prevent Left Ventricular Remodeling After Acute Myocardial Infarction]] | ||
|- | |- | ||
| PREPAIR | | [[PREPAIR]] | ||
| [[Clopidogrel 600-Mg Double Loading Dose Achieves Stronger Platelet Inhibition Than Conventional Regimens]] | | [[Clopidogrel 600-Mg Double Loading Dose Achieves Stronger Platelet Inhibition Than Conventional Regimens]] | ||
|- | |- | ||
| PREPARE — Presented at TCT 2008 | | [[PREPARE — Presented at TCT 2008]] | ||
| [[Proximal Embolic Protection In Acute Mi And Resolution Of St-Elevation]] | | [[Proximal Embolic Protection In Acute Mi And Resolution Of St-Elevation]] | ||
|- | |- | ||
| PREPIC | | [[PREPIC]] | ||
| [[A Clinical Trial Of Vena Caval Filters In The Prevention Of Pulmonary Embolism In Patients With Proximal Deep-Vein Thrombosis]] | | [[A Clinical Trial Of Vena Caval Filters In The Prevention Of Pulmonary Embolism In Patients With Proximal Deep-Vein Thrombosis]] | ||
|- | |- | ||
| Pre-RELAX-AHF | | [[Pre-RELAX-AHF]] | ||
| [[Preliminary Study Of Relaxin In Acute Heart Failure]] | | [[Preliminary Study Of Relaxin In Acute Heart Failure]] | ||
|- | |- | ||
| PRESENT | | [[PRESENT]] | ||
| [[Preliminary Safety Evaluation Of Nanoporous Tacrolimus Eluting Stents]] | | [[Preliminary Safety Evaluation Of Nanoporous Tacrolimus Eluting Stents]] | ||
|- | |- | ||
| PRESERVE | | [[PRESERVE]] | ||
| [[Prospective Randomized Trial Of Enalapril To Reverse Ventricular Enlargement]] | | [[Prospective Randomized Trial Of Enalapril To Reverse Ventricular Enlargement]] | ||
|- | |- | ||
| PRESTO | | [[PRESTO]] | ||
| [[Results Of Prevention Of Restenosis With Tranilast And Its Outcomes (Presto) Trial.]] | | [[Results Of Prevention Of Restenosis With Tranilast And Its Outcomes (Presto) Trial.]] | ||
|- | |- | ||
| PREVEND IT | | [[PREVEND IT]] | ||
| [[Prevention Of Renal And Vascular End-Stage Disease Intervention Trial]] | | [[Prevention Of Renal And Vascular End-Stage Disease Intervention Trial]] | ||
|- | |- | ||
| PREVENT | | [[PREVENT]] | ||
| [[Prospective Randomized Evaluation Of The Vascular Effects Of Norvasc Trial]] | | [[Prospective Randomized Evaluation Of The Vascular Effects Of Norvasc Trial]] | ||
|- | |- | ||
| PREVENT (Dalteparin) | | [[PREVENT (Dalteparin)]] | ||
| [[Prospective Evaluation Of Dalteparin Efficacy For Prevention Of Vte In Immobilized Patients Trial]] | | [[Prospective Evaluation Of Dalteparin Efficacy For Prevention Of Vte In Immobilized Patients Trial]] | ||
|- | |- | ||
| PREVENT (Warfarin) | | [[PREVENT (Warfarin)]] | ||
| [[Prevention Of Recurrent Venous Thromboembolism]] | | [[Prevention Of Recurrent Venous Thromboembolism]] | ||
|- | |- | ||
| PREVENT II | | [[PREVENT II]] | ||
| [[The Program In Ex Vivo Vein Graft Engineering Via Transfection II Study: E2F Decoy In Cabg]] | | [[The Program In Ex Vivo Vein Graft Engineering Via Transfection II Study: E2F Decoy In Cabg]] | ||
|- | |- | ||
| PREVENT IV | | [[PREVENT IV]] | ||
| [[Project Of Ex-Vivo Vein Graft Engineering Via Transfection]] | | [[Project Of Ex-Vivo Vein Graft Engineering Via Transfection]] | ||
|- | |- | ||
| PREVENT(Radiation) | | [[PREVENT(Radiation)]] | ||
| [[Proliferation Reduction With Vascular Energy Trial]] | | [[Proliferation Reduction With Vascular Energy Trial]] | ||
|- | |- | ||
| PRIDE | | [[PRIDE]] | ||
| [[A Prospective, Randomized, Controlled Trial Of Distal Protection With The Kensey-Nash Triactiv System Compared To The Guardwire Or Filterwire]] | | [[A Prospective, Randomized, Controlled Trial Of Distal Protection With The Kensey-Nash Triactiv System Compared To The Guardwire Or Filterwire]] | ||
|- | |- | ||
| PRIMA — Presented at ACC.09/i2 | | [[PRIMA — Presented at ACC.09/i2]] | ||
| [[Can Pro-Brain Natriuretic Peptide Guided Therapy Of Heart Failure Improve Heart Failure Morbidity And Mortality?]] | | [[Can Pro-Brain Natriuretic Peptide Guided Therapy Of Heart Failure Improve Heart Failure Morbidity And Mortality?]] | ||
|- | |- | ||
| PRIME-2 | | [[PRIME-2]] | ||
| [[Second Prospective Randomized Study Of Ibopamine On Mortality And Efficacy In Heart Failure]] | | [[Second Prospective Randomized Study Of Ibopamine On Mortality And Efficacy In Heart Failure]] | ||
|- | |- | ||
| PRIMI | | [[PRIMI]] | ||
| [[Pro-Urokinase For Myocardial Infarction]] | | [[Pro-Urokinase For Myocardial Infarction]] | ||
|- | |- | ||
| PRIMO-CABG | | [[PRIMO-CABG]] | ||
| [[Pexelizumab For The Reduction Of Infarction And Mortality In Coronary Artery Bypass Graft Surgery Study]] | | [[Pexelizumab For The Reduction Of Infarction And Mortality In Coronary Artery Bypass Graft Surgery Study]] | ||
|- | |- | ||
| PRIMO-CABG II | | [[PRIMO-CABG II]] | ||
| [[Pexelizumab For The Reduction Of Infarction And Mortality In Coronary Artery Bypass Graft II]] | | [[Pexelizumab For The Reduction Of Infarction And Mortality In Coronary Artery Bypass Graft II]] | ||
|- | |- | ||
| PRINCE | | [[PRINCE]] | ||
| [[Effect Of Statin Therapy On C-Reactive Protein Levels: The Pravastatin Inflammation/Crp Evaluation (Prince): A Randomized Trial And Cohort Study]] | | [[Effect Of Statin Therapy On C-Reactive Protein Levels: The Pravastatin Inflammation/Crp Evaluation (Prince): A Randomized Trial And Cohort Study]] | ||
|- | |- | ||
| PRINCESS | | [[PRINCESS]] | ||
| [[Prevention Of Ischaemic Events By Early Treatment Of Cerivastatin After Acute Myocardial Infarction]] | | [[Prevention Of Ischaemic Events By Early Treatment Of Cerivastatin After Acute Myocardial Infarction]] | ||
|- | |- | ||
| PRINCIPLE-TIMI 44 | | [[PRINCIPLE-TIMI 44]] | ||
| [[The Prasugrel In Comparison To Clopidogrel For Inhibition Of Platelet Activation And Aggregation–Thrombolysis In Myocardial Infarction 44 Trial]] | | [[The Prasugrel In Comparison To Clopidogrel For Inhibition Of Platelet Activation And Aggregation–Thrombolysis In Myocardial Infarction 44 Trial]] | ||
|- | |- | ||
| PRISM | | [[PRISM]] | ||
| [[Platelet-Receptor Inhibition For Ischemic Syndrome Management]] | | [[Platelet-Receptor Inhibition For Ischemic Syndrome Management]] | ||
|- | |- | ||
| PRISM-PLUS | | [[PRISM-PLUS]] | ||
| [[Platelet-Receptor Inhibition For Ischemic Syndrome Management In Patients Limited By Unstable Signs And Symptoms]] | | [[Platelet-Receptor Inhibition For Ischemic Syndrome Management In Patients Limited By Unstable Signs And Symptoms]] | ||
|- | |- | ||
| PRISM-Troponin | | [[PRISM-Troponin]] | ||
| [[Troponin Levels Identify Cad Patients Likely To Benefit From Tirofiban: Results From The Prism-Troponin Study, A Substudy Of The Platelet Receptor Inhibition In Ischemic Syndrome Management Study]] | | [[Troponin Levels Identify Cad Patients Likely To Benefit From Tirofiban: Results From The Prism-Troponin Study, A Substudy Of The Platelet Receptor Inhibition In Ischemic Syndrome Management Study]] | ||
|- | |- | ||
| PRISON II | | [[PRISON II]] | ||
| [[Prospective Randomized Trial Of Sirolimus-Eluting And Bare Metal Stents In Patients With Chronic Total Occlusions]] | | [[Prospective Randomized Trial Of Sirolimus-Eluting And Bare Metal Stents In Patients With Chronic Total Occlusions]] | ||
|- | |- | ||
| PROactive | | [[PROactive]] | ||
| [[Prospective Pioglitazone Clinical Trial In Macrovascular Events]] | | [[Prospective Pioglitazone Clinical Trial In Macrovascular Events]] | ||
|- | |- | ||
| PROCAM | | [[PROCAM]] | ||
| [[Simple Scoring Scheme For Calculating The Risk Of Acute Coronary Events Based On The 10-Year Follow-Up Of The Prospective Cardiovascular Münster (Procam) Study]] | | [[Simple Scoring Scheme For Calculating The Risk Of Acute Coronary Events Based On The 10-Year Follow-Up Of The Prospective Cardiovascular Münster (Procam) Study]] | ||
|- | |- | ||
| PRoFESS | | [[PRoFESS]] | ||
| [[Prevention Regimen For Effectively Avoiding Second Strokes]] | | [[Prevention Regimen For Effectively Avoiding Second Strokes]] | ||
|- | |- | ||
| PROFILE | | [[PROFILE]] | ||
| [[Prospective Randomized Flosequinan Longevity Evaluation]] | | [[Prospective Randomized Flosequinan Longevity Evaluation]] | ||
|- | |- | ||
| PROGRESS | | [[PROGRESS]] | ||
| [[Perindopril Protection Against Recurrent Stroke Study]] | | [[Perindopril Protection Against Recurrent Stroke Study]] | ||
|- | |- | ||
| PROGRESS-1 | | [[PROGRESS-1]] | ||
| [[Coronary Stenting With Absorbable Metal Stents]] | | [[Coronary Stenting With Absorbable Metal Stents]] | ||
|- | |- | ||
| PROMISE | | [[PROMISE]] | ||
| [[Protection Devices In Pci-Treatment Of Myocardial Infarction For Salvage Of Endangered Myocardium Study]] | | [[Protection Devices In Pci-Treatment Of Myocardial Infarction For Salvage Of Endangered Myocardium Study]] | ||
|- | |- | ||
| PROMISE | | [[PROMISE]] | ||
| [[The Effects Of Oral Milrinone On Mortality In Severe Chronic Heart Failure]] | | [[The Effects Of Oral Milrinone On Mortality In Severe Chronic Heart Failure]] | ||
|- | |- | ||
| PROSPER | | [[PROSPER]] | ||
| [[Prospective Study Of Pravastatin In The Elderly At Risk]] | | [[Prospective Study Of Pravastatin In The Elderly At Risk]] | ||
|- | |- | ||
| PROTECT - TIMI 30 | | [[PROTECT - TIMI 30]] | ||
| [[Randomized Trial To Evaluate The Relative Protection Against Post-Pci Microvascular Dysfunction And Post-Pca Ischemia Among Anti-Platelet And Anti-Thrombotic Agents]] | | [[Randomized Trial To Evaluate The Relative Protection Against Post-Pci Microvascular Dysfunction And Post-Pca Ischemia Among Anti-Platelet And Anti-Thrombotic Agents]] | ||
|- | |- | ||
| PROTECT AF | | [[PROTECT AF]] | ||
| [[Randomized Prospective Trial Of Percutaneous Left Atrial Appendage Closure Versus Warfarin For Stroke Prevention In Atrial Fibrillation]] | | [[Randomized Prospective Trial Of Percutaneous Left Atrial Appendage Closure Versus Warfarin For Stroke Prevention In Atrial Fibrillation]] | ||
|- | |- | ||
| PROTECT-CAD | | [[PROTECT-CAD]] | ||
| [[Prospective Randomized Trial Of Direct Endomyocardial Implantation Of Bone Marrow Cells For Therapeutic Angiogenesis In Coronary Artery Diseases]] | | [[Prospective Randomized Trial Of Direct Endomyocardial Implantation Of Bone Marrow Cells For Therapeutic Angiogenesis In Coronary Artery Diseases]] | ||
|- | |- | ||
| PROVE IT/TIMI 22 | | [[PROVE IT/TIMI 22]] | ||
| [[Pravastatin Or Atorvastatin Evaluation And Infection Therapy: Thrombolysis In Myocardial Infarction 22]] | | [[Pravastatin Or Atorvastatin Evaluation And Infection Therapy: Thrombolysis In Myocardial Infarction 22]] | ||
|- | |- | ||
| PROVE IT-TIMI 22 (Gatifloxacin) | | [[PROVE IT-TIMI 22 (Gatifloxacin)]] | ||
| [[Pravastatin Or Atorvastatin Evaluation And Infection Therapy]] | | [[Pravastatin Or Atorvastatin Evaluation And Infection Therapy]] | ||
|- | |- | ||
| PROVED | | [[PROVED]] | ||
| [[Randomized Study Assessing The Effect Of Digoxin Withdrawal In Patients With Mild To Moderate Chronic Congestive Heart Failure: Results Of The Proved]] | | [[Randomized Study Assessing The Effect Of Digoxin Withdrawal In Patients With Mild To Moderate Chronic Congestive Heart Failure: Results Of The Proved]] | ||
|- | |- | ||
| PROVIDENCE 1 | | [[PROVIDENCE 1]] | ||
| [[Prospective Evaluation Of Rifalazil Effect On Vascular Symptoms Of Intermittent Claudication And Other Endpoints In Chlamydia Seropositive Patients]] | | [[Prospective Evaluation Of Rifalazil Effect On Vascular Symptoms Of Intermittent Claudication And Other Endpoints In Chlamydia Seropositive Patients]] | ||
|- | |- | ||
| PROXIMAL | | [[PROXIMAL]] | ||
| [[Proximal Protection During Saphenous Vein Graft Intervention]] | | [[Proximal Protection During Saphenous Vein Graft Intervention]] | ||
|- | |- | ||
| PURSUIT | | [[PURSUIT]] | ||
| [[Platelet Glycoprotein IIb/IIia In Unstable Angina:Receptor Suppression Using Integrilin Therapy]] | | [[Platelet Glycoprotein IIb/IIia In Unstable Angina:Receptor Suppression Using Integrilin Therapy]] | ||
|- | |- | ||
| QUASAR | | [[QUASAR]] | ||
| [[Quinapril Anti-Ischemia And Symptoms Of Angina Reduction]] | | [[Quinapril Anti-Ischemia And Symptoms Of Angina Reduction]] | ||
|- | |- | ||
| QUIET | | [[QUIET]] | ||
| [[Quinapril Ischemic Event Trial]] | | [[Quinapril Ischemic Event Trial]] | ||
|- | |- | ||
| R3 | | [[R3]] | ||
| [[Reopro Readministration Registry]] | | [[Reopro Readministration Registry]] | ||
|- | |- | ||
| RAAMI | | [[RAAMI]] | ||
| [[Randomized Angiographic Trial Of Recombinant Tissue-Type Plasminogen Activator (Alteplase) In Myocardial Infarction]] | | [[Randomized Angiographic Trial Of Recombinant Tissue-Type Plasminogen Activator (Alteplase) In Myocardial Infarction]] | ||
|- | |- | ||
| RABBIT II | | [[RABBIT II]] | ||
| [[Randomized Angioplasty Beta Blocker Intracoronary Trial II]] | | [[Randomized Angioplasty Beta Blocker Intracoronary Trial II]] | ||
|- | |- | ||
| RACE | | [[RACE]] | ||
| [[Rate Control Versus Electrical Cardioversion For Persistent Atrial Fibrillation]] | | [[Rate Control Versus Electrical Cardioversion For Persistent Atrial Fibrillation]] | ||
|- | |- | ||
| RACS | | [[RACS]] | ||
| [[Randomized Argentine Clopidogrel Stent Trial]] | | [[Randomized Argentine Clopidogrel Stent Trial]] | ||
|- | |- | ||
| RACTS | | [[RACTS]] | ||
| [[A Prospective, Randomized Multicenter Trial Of Cilostozal Vs Ticlopidine In Patients Undergoing Stent Implantation]] | | [[A Prospective, Randomized Multicenter Trial Of Cilostozal Vs Ticlopidine In Patients Undergoing Stent Implantation]] | ||
|- | |- | ||
| RADIANCE | | [[RADIANCE]] | ||
| [[Withdrawal Of Digoxin From Patients With Chronic Heart Failure Treated With Angiotensin-Converting Enzyme Inhibitors]] | | [[Withdrawal Of Digoxin From Patients With Chronic Heart Failure Treated With Angiotensin-Converting Enzyme Inhibitors]] | ||
|- | |- | ||
| RADIANCE 1 | | [[RADIANCE 1]] | ||
| [[Rating Atherosclerotic Disease Change By Imaging With A New Cetp Inhibitor]] | | [[Rating Atherosclerotic Disease Change By Imaging With A New Cetp Inhibitor]] | ||
|- | |- | ||
| RADIANCE 2 | | [[RADIANCE 2]] | ||
| [[Rating Atherosclerotic Disease Change By Imaging With A New Cetp Inhibitor - 2]] | | [[Rating Atherosclerotic Disease Change By Imaging With A New Cetp Inhibitor - 2]] | ||
|- | |- | ||
| RALES | | [[RALES]] | ||
| [[Randomized Aldactone Evaluation Study]] | | [[Randomized Aldactone Evaluation Study]] | ||
|- | |- | ||
| RaMI | | [[RaMI]] | ||
| [[Prehospital Thrombolysis In Rural Emergency Room And Subsequent Transport To A Coronary Care Unit: Ravenna Myocardial Infarction (Rami) Trial]] | | [[Prehospital Thrombolysis In Rural Emergency Room And Subsequent Transport To A Coronary Care Unit: Ravenna Myocardial Infarction (Rami) Trial]] | ||
|- | |- | ||
| RAPID-1 | | [[RAPID-1]] | ||
| [[Recombinant Plasminogen Activator Angiographic Phase II International Dose-Finding Study]] | | [[Recombinant Plasminogen Activator Angiographic Phase II International Dose-Finding Study]] | ||
|- | |- | ||
| RAPID-2 | | [[RAPID-2]] | ||
| [[Reteplase Vs Alteplase Patency Investigation During Myocardial Infarction]] | | [[Reteplase Vs Alteplase Patency Investigation During Myocardial Infarction]] | ||
|- | |- | ||
| RAPPORT | | [[RAPPORT]] | ||
| [[Reopro And Primary Ptca Organization And Randomized Trial]] | | [[Reopro And Primary Ptca Organization And Randomized Trial]] | ||
|- | |- | ||
| RAPS | | [[RAPS]] | ||
| [[Radial Artery Patency Study]] | | [[Radial Artery Patency Study]] | ||
|- | |- | ||
| RAPT | | [[RAPT]] | ||
| [[Ridogrel Versus Aspirin Patency Trial]] | | [[Ridogrel Versus Aspirin Patency Trial]] | ||
|- | |- | ||
| RAVE | | [[RAVE]] | ||
| [[Regional Angiogenesis With Vascular Endothelial Growth Factor In Peripheral Arterial Disease]] | | [[Regional Angiogenesis With Vascular Endothelial Growth Factor In Peripheral Arterial Disease]] | ||
|- | |- | ||
| RAVEL | | [[RAVEL]] | ||
| [[A Randomized Comparison Of A Sirolimus-Eluting Stent With A Standard Stent For Coronary Revascularization]] | | [[A Randomized Comparison Of A Sirolimus-Eluting Stent With A Standard Stent For Coronary Revascularization]] | ||
|- | |- | ||
| REACH | | [[REACH]] | ||
| [[Reinforcing Education About Cholesterol]] | | [[Reinforcing Education About Cholesterol]] | ||
|- | |- | ||
| REACH Registry | | [[REACH Registry]] | ||
| [[Reduction Of Atherothrombosis For Continued Health Registry]] | | [[Reduction Of Atherothrombosis For Continued Health Registry]] | ||
|- | |- | ||
| REACT | | [[REACT]] | ||
| [[Rescue Angioplasty Versus Conservative Therapy Or Repeat Thrombolysis Trial]] | | [[Rescue Angioplasty Versus Conservative Therapy Or Repeat Thrombolysis Trial]] | ||
|- | |- | ||
| REACT | | [[REACT]] | ||
| [[Rapid Early Action For Coronary Treatment]] | | [[Rapid Early Action For Coronary Treatment]] | ||
|- | |- | ||
| REALITY | | [[REALITY]] | ||
| [[Prospective Randomized Multi-Center Head-To-Head Comparison Of The Sirolimus-Eluting Stent (Cypher) And The Paclitaxel-Eluting Stent (Taxus]] | | [[Prospective Randomized Multi-Center Head-To-Head Comparison Of The Sirolimus-Eluting Stent (Cypher) And The Paclitaxel-Eluting Stent (Taxus]] | ||
|- | |- | ||
| RECORD | | [[RECORD]] | ||
| [[Rosiglitazone Evaluated For Cardiovascular Outcomes — An Interim Analysis]] | | [[Rosiglitazone Evaluated For Cardiovascular Outcomes — An Interim Analysis]] | ||
|- | |- | ||
| RECORD1 | | [[RECORD1]] | ||
| [[Regulation Of Coagulation In Orthopedic Surgery To Prevent Deep Venous Thrombosis And Pulmonary Embolism 1]] | | [[Regulation Of Coagulation In Orthopedic Surgery To Prevent Deep Venous Thrombosis And Pulmonary Embolism 1]] | ||
|- | |- | ||
| RECORD2 | | [[RECORD2]] | ||
| [[Regulation Of Coagulation In Orthopedic Surgery To Prevent Deep Venous Thrombosis And Pulmonary Embolism 2]] | | [[Regulation Of Coagulation In Orthopedic Surgery To Prevent Deep Venous Thrombosis And Pulmonary Embolism 2]] | ||
|- | |- | ||
| RECORD3 | | [[RECORD3]] | ||
| [[Regulation Of Coagulation In Orthopedic Surgery To Prevent Deep Venous Thrombosis And Pulmonary Embolism 3]] | | [[Regulation Of Coagulation In Orthopedic Surgery To Prevent Deep Venous Thrombosis And Pulmonary Embolism 3]] | ||
|- | |- | ||
| RECOVER | | [[RECOVER]] | ||
| [[Renal Toxicity Evaluation And Comparison Between Visipaque And Hexabrix In Patients With Renal Insufficiency Undergoing Coronary Angiography]] | | [[Renal Toxicity Evaluation And Comparison Between Visipaque And Hexabrix In Patients With Renal Insufficiency Undergoing Coronary Angiography]] | ||
|- | |- | ||
| RECOVERS | | [[RECOVERS]] | ||
| [[Randomized Evaluation Of Polytetrafluoroethylene-Covered Stent In Saphenous Vein Grafts]] | | [[Randomized Evaluation Of Polytetrafluoroethylene-Covered Stent In Saphenous Vein Grafts]] | ||
|- | |- | ||
| REDHOT | | [[REDHOT]] | ||
| [[Rapid Emergency Department Heart Failure Outpatient Trial]] | | [[Rapid Emergency Department Heart Failure Outpatient Trial]] | ||
|- | |- | ||
| RED-LIP | | [[RED-LIP]] | ||
| [[Trial Of Pravastatin In Primary Isolated Hypercholesterolemia]] | | [[Trial Of Pravastatin In Primary Isolated Hypercholesterolemia]] | ||
|- | |- | ||
| REDUCE | | [[REDUCE]] | ||
| [[Low Molecular Weight Heparin (Reviparin) In Percutaneous Transluminal Coronary Angioplasty]] | | [[Low Molecular Weight Heparin (Reviparin) In Percutaneous Transluminal Coronary Angioplasty]] | ||
|- | |- | ||
| REDUCE III | | [[REDUCE III]] | ||
| [[A Prospective, Randomized Multicenter Trial Of Cutting Balloon Before Stenting In Patients Undergoing Pci]] | | [[A Prospective, Randomized Multicenter Trial Of Cutting Balloon Before Stenting In Patients Undergoing Pci]] | ||
|- | |- | ||
| REFLECT | | [[REFLECT]] | ||
| [[Double-Blind, Placebo-Controlled Study Of The Efficacy Of Flosequinan In Patients With Chronic Heart Failure]] | | [[Double-Blind, Placebo-Controlled Study Of The Efficacy Of Flosequinan In Patients With Chronic Heart Failure]] | ||
|- | |- | ||
| REGENT | | [[REGENT]] | ||
| [[Myocardial Regeneration By Intracoronary Infusion Of Selected Population Of Stem Cells In Acute Myocardial Infarction]] | | [[Myocardial Regeneration By Intracoronary Infusion Of Selected Population Of Stem Cells In Acute Myocardial Infarction]] | ||
|- | |- | ||
| REGICOR | | [[REGICOR]] | ||
| [[Improvement In Survival After Myocardial Infarction Between 1978-85 And 1986-88 In The Regicor Study]] | | [[Improvement In Survival After Myocardial Infarction Between 1978-85 And 1986-88 In The Regicor Study]] | ||
|- | |- | ||
| REGRESS | | [[REGRESS]] | ||
| [[Effects Of Lipid Lowering By Pravastatin On Progression And Regression Of Coronary Artery Disease In Symptomatic Men With Normal To Moderately Elevated Serum Cholesterol Levels. The Regression Growth Evaluation Statin Study (Regress)]] | | [[Effects Of Lipid Lowering By Pravastatin On Progression And Regression Of Coronary Artery Disease In Symptomatic Men With Normal To Moderately Elevated Serum Cholesterol Levels. The Regression Growth Evaluation Statin Study (Regress)]] | ||
|- | |- | ||
| RELAx-AMI | | [[RELAx-AMI]] | ||
| [[Randomized Early Versus Late Abciximab In Acute Myocardial Infarction Treated With Primary Coronary Intervention]] | | [[Randomized Early Versus Late Abciximab In Acute Myocardial Infarction Treated With Primary Coronary Intervention]] | ||
|- | |- | ||
| RELOAD | | [[RELOAD]] | ||
| [[Reload With Clopidogrel Before Coronary Angioplasty In Subjects Treated Long Term With Dual Antiplatelet Therapy]] | | [[Reload With Clopidogrel Before Coronary Angioplasty In Subjects Treated Long Term With Dual Antiplatelet Therapy]] | ||
|- | |- | ||
| REMATCH | | [[REMATCH]] | ||
| [[Randomized Evaluation Of Mechanical Assistance For The Treatment Of Congestive Heart Failure]] | | [[Randomized Evaluation Of Mechanical Assistance For The Treatment Of Congestive Heart Failure]] | ||
|- | |- | ||
| REMEDIA | | [[REMEDIA]] | ||
| [[Randomized Evaluation Of The Effect Of Mechanical Reduction Of Distal Embolization By Thrombus-Aspiration In Primary And Rescue Angioplasty]] | | [[Randomized Evaluation Of The Effect Of Mechanical Reduction Of Distal Embolization By Thrombus-Aspiration In Primary And Rescue Angioplasty]] | ||
|- | |- | ||
| REMEDIAL | | [[REMEDIAL]] | ||
| [[Renal Insufficiency Following Contrast Media Administration Trial]] | | [[Renal Insufficiency Following Contrast Media Administration Trial]] | ||
|- | |- | ||
| RENAAL | | [[RENAAL]] | ||
| [[Effects Of Losartan On Renal And Cardiovascular Outcomes In Patients With Type 2 Diabetes And Nephropathy]] | | [[Effects Of Losartan On Renal And Cardiovascular Outcomes In Patients With Type 2 Diabetes And Nephropathy]] | ||
|- | |- | ||
| RENEWAL - RECOVER | | [[RENEWAL - RECOVER]] | ||
| [[Research Into Etanercept Cytokine Antagonism In Ventricular Dysfunction]] | | [[Research Into Etanercept Cytokine Antagonism In Ventricular Dysfunction]] | ||
|- | |- | ||
| RENEWAL - RENAISSANCE | | [[RENEWAL - RENAISSANCE]] | ||
| [[Randomized Etanercept North American Strategy To Study Antagonism Of Cytokines]] | | [[Randomized Etanercept North American Strategy To Study Antagonism Of Cytokines]] | ||
|- | |- | ||
| REPAIR-AMI | | [[REPAIR-AMI]] | ||
| [[Reinfusion Of Enriched Progenitor Cells And Infarct Remodeling In Acute Myocardial Infarction]] | | [[Reinfusion Of Enriched Progenitor Cells And Infarct Remodeling In Acute Myocardial Infarction]] | ||
|- | |- | ||
| REPLACE 2 | | [[REPLACE 2]] | ||
| [[Randomized Evaluation Of Pci Linking Angiomax To Reduced Clinical Events]] | | [[Randomized Evaluation Of Pci Linking Angiomax To Reduced Clinical Events]] | ||
|- | |- | ||
| RESCUE | | [[RESCUE]] | ||
| [[Randomized Evaluation Of Salvage Angioplasty With Combined Utilization Of Endpoints]] | | [[Randomized Evaluation Of Salvage Angioplasty With Combined Utilization Of Endpoints]] | ||
|- | |- | ||
| RESEARCH | | [[RESEARCH]] | ||
| [[Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital Registry]] | | [[Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital Registry]] | ||
|- | |- | ||
| RESIST | | [[RESIST]] | ||
| [[Impact Of Intravascular Ultrasound Guidance In Stent Deployment On 6-Month Restenosis Rate: A Multicenter, Randomized Study Comparing Two Strategies--With And Without Intravascular Ultrasound Guidance]] | | [[Impact Of Intravascular Ultrasound Guidance In Stent Deployment On 6-Month Restenosis Rate: A Multicenter, Randomized Study Comparing Two Strategies--With And Without Intravascular Ultrasound Guidance]] | ||
|- | |- | ||
| RESOLVD | | [[RESOLVD]] | ||
| [[Randomized Evaluation Of Strategies For Left Ventricular Dysfunction Pilot]] | | [[Randomized Evaluation Of Strategies For Left Ventricular Dysfunction Pilot]] | ||
|- | |- | ||
| REST | | [[REST]] | ||
| [[Restenosis Stent Trial]] | | [[Restenosis Stent Trial]] | ||
|- | |- | ||
| Restenosis Stent | | [[Restenosis Stent]] | ||
| [[Coronary-Artery Stenting Compared With Balloon Angioplasty For Restenosis After Initial Balloon Angioplasty]] | | [[Coronary-Artery Stenting Compared With Balloon Angioplasty For Restenosis After Initial Balloon Angioplasty]] | ||
|- | |- | ||
| RESTORE | | [[RESTORE]] | ||
| [[Randomized Efficacy Study Of Tirofiban For Outcome And Restenosis]] | | [[Randomized Efficacy Study Of Tirofiban For Outcome And Restenosis]] | ||
|- | |- | ||
| RethinQ | | [[RethinQ]] | ||
| [[Resynchronization Therapy In Patients With Narrow Qrs]] | | [[Resynchronization Therapy In Patients With Narrow Qrs]] | ||
|- | |- | ||
| REVERSAL | | [[REVERSAL]] | ||
| [[Reversing Atherosclerosis With Aggressive Lipid Lowering]] | | [[Reversing Atherosclerosis With Aggressive Lipid Lowering]] | ||
|- | |- | ||
| REVERSE | | [[REVERSE]] | ||
| [[Resynchronization Reverses Remodeling In Systolic Left Ventricular Dysfunction]] | | [[Resynchronization Reverses Remodeling In Systolic Left Ventricular Dysfunction]] | ||
|- | |- | ||
| REVERT | | [[REVERT]] | ||
| [[Reversal Of Ventricular Remodeling With Toprol-Xl]] | | [[Reversal Of Ventricular Remodeling With Toprol-Xl]] | ||
|- | |- | ||
| REVIVAL-3 | | [[REVIVAL-3]] | ||
| [[The Regeneration Of Vital Myocardium In St-Segment Elevation Myocardial Infarction By Erythropoietin]] | | [[The Regeneration Of Vital Myocardium In St-Segment Elevation Myocardial Infarction By Erythropoietin]] | ||
|- | |- | ||
| RHYTHM II ICD | | [[RHYTHM II ICD]] | ||
| [[Resynchronization For The Hemodynamic Treatment For Heart Failure Management II Implantable Cardioverter Defibrillator]] | | [[Resynchronization For The Hemodynamic Treatment For Heart Failure Management II Implantable Cardioverter Defibrillator]] | ||
|- | |- | ||
| RIO-Europe | | [[RIO-Europe]] | ||
| [[A Randomized Double-Blind Study Of Weight Reducing Effect And Safety Of Rimonabant In Obese Patients With Or Without Comorbidities]] | | [[A Randomized Double-Blind Study Of Weight Reducing Effect And Safety Of Rimonabant In Obese Patients With Or Without Comorbidities]] | ||
|- | |- | ||
| RIO-Lipids | | [[RIO-Lipids]] | ||
| [[Rimonabant In Obesity]] | | [[Rimonabant In Obesity]] | ||
|- | |- | ||
| RIO-NA | | [[RIO-NA]] | ||
| [[Rimonabant On Weight Reduction And Weight Maintenance: Rio-North America]] | | [[Rimonabant On Weight Reduction And Weight Maintenance: Rio-North America]] | ||
|- | |- | ||
| RIS | | [[RIS]] | ||
| [[Efficacy Of Multiple Risk Factor Intervention In Treated Hypertensive Men]] | | [[Efficacy Of Multiple Risk Factor Intervention In Treated Hypertensive Men]] | ||
|- | |- | ||
| RISC | | [[RISC]] | ||
| [[Research On Instability In Coronary Artery Disease]] | | [[Research On Instability In Coronary Artery Disease]] | ||
|- | |- | ||
| RITA | | [[RITA]] | ||
| [[Randomized Intervention Treatment Of Angina Trial]] | | [[Randomized Intervention Treatment Of Angina Trial]] | ||
|- | |- | ||
| RITA II | | [[RITA II]] | ||
| [[The Second Randomized Intervention Treatment Of Angina]] | | [[The Second Randomized Intervention Treatment Of Angina]] | ||
|- | |- | ||
| RITA-3 | | [[RITA-3]] | ||
| [[Randomized Trial Of A Conservative Treatment Strategy Versus An Interventional Treatment Strategy In Patients With Unstable Angina]] | | [[Randomized Trial Of A Conservative Treatment Strategy Versus An Interventional Treatment Strategy In Patients With Unstable Angina]] | ||
|- | |- | ||
| RITZ 2 | | [[RITZ 2]] | ||
| [[Randomized Intravenous Tezosentan For The Treatment Of Acute Heart Failure]] | | [[Randomized Intravenous Tezosentan For The Treatment Of Acute Heart Failure]] | ||
|- | |- | ||
| RITZ-4 | | [[RITZ-4]] | ||
| [[Randomized Intravenous Tezosentan Study]] | | [[Randomized Intravenous Tezosentan Study]] | ||
|- | |- | ||
| RIVIERA Registry | | [[RIVIERA Registry]] | ||
| [[Registry On Intra-Venous Anticoagulation In The Elective And Primary Real World Of Angioplasty]] | | [[Registry On Intra-Venous Anticoagulation In The Elective And Primary Real World Of Angioplasty]] | ||
|- | |- | ||
| ROADMAP | | [[ROADMAP]] | ||
| [[Randomized Olmesartan And Diabetes Microalbuminuria Prevention Trial]] | | [[Randomized Olmesartan And Diabetes Microalbuminuria Prevention Trial]] | ||
|- | |- | ||
| ROBUST | | [[ROBUST]] | ||
| [[Recanalization Of Chronically Occluded Aorto-Coronary Saphenous Vein Bypass Grafts With Long-Term, Low Dose Direct Infusion Of Urokinase Trial]] | | [[Recanalization Of Chronically Occluded Aorto-Coronary Saphenous Vein Bypass Grafts With Long-Term, Low Dose Direct Infusion Of Urokinase Trial]] | ||
|- | |- | ||
| ROMAS | | [[ROMAS]] | ||
| [[Romanian Multicenter Study - Accelerated Streptokinase In Acute Myocardial Infarction]] | | [[Romanian Multicenter Study - Accelerated Streptokinase In Acute Myocardial Infarction]] | ||
|- | |- | ||
| ROSTER | | [[ROSTER]] | ||
| [[Randomized Trial Of Rotational Atherectomy Versus Balloon Angioplasty For Diffuse In-Stent Restenosis]] | | [[Randomized Trial Of Rotational Atherectomy Versus Balloon Angioplasty For Diffuse In-Stent Restenosis]] | ||
|- | |- | ||
| ROXIS | | [[ROXIS]] | ||
| [[Roxithromycin In Non-Q Wave Coronary Syndromes]] | | [[Roxithromycin In Non-Q Wave Coronary Syndromes]] | ||
|- | |- | ||
| RSVP | | [[RSVP]] | ||
| [[Radial Artery Versus Saphenous Vein Patency]] | | [[Radial Artery Versus Saphenous Vein Patency]] | ||
|- | |- | ||
| RUSSLAN | | [[RUSSLAN]] | ||
| [[Safety And Efficacy Of A Novel Calcium Sensitizer, Levosimendan, In Patients With Left Ventricular Failure Due To An Acute Myocardial Infarction]] | | [[Safety And Efficacy Of A Novel Calcium Sensitizer, Levosimendan, In Patients With Left Ventricular Failure Due To An Acute Myocardial Infarction]] | ||
|- | |- | ||
| RUTH | | [[RUTH]] | ||
| [[Raloxifene Use For The Heart]] | | [[Raloxifene Use For The Heart]] | ||
|- | |- | ||
| SADHART | | [[SADHART]] | ||
| [[Sertraline Treatment Of Major Depression In Patients With Acute Mi Or Unstable Angina]] | | [[Sertraline Treatment Of Major Depression In Patients With Acute Mi Or Unstable Angina]] | ||
|- | |- | ||
| SAFE | | [[SAFE]] | ||
| [[Safety After Fifty Evaluation]] | | [[Safety After Fifty Evaluation]] | ||
|- | |- | ||
| SAFER | | [[SAFER]] | ||
| [[The Saphenous Vein Graft Angioplasty Free Of Emboli Randomized Trial]] | | [[The Saphenous Vein Graft Angioplasty Free Of Emboli Randomized Trial]] | ||
|- | |- | ||
| SAFE-T | | [[SAFE-T]] | ||
| [[Sotalol Amiodarone Atrial Fibrillation Efficacy Trial]] | | [[Sotalol Amiodarone Atrial Fibrillation Efficacy Trial]] | ||
|- | |- | ||
| SAGE | | [[SAGE]] | ||
| [[Study Assessing Goals In The Elderly]] | | [[Study Assessing Goals In The Elderly]] | ||
|- | |- | ||
| SALT | | [[SALT]] | ||
| [[Swedish Aspirin Low-Dose Trial]] | | [[Swedish Aspirin Low-Dose Trial]] | ||
|- | |- | ||
| SALT 1 and 2 | | [[SALT 1 and 2]] | ||
| [[Study Of Ascending Levels Of Tolvaptan In Hyponatremia]] | | [[Study Of Ascending Levels Of Tolvaptan In Hyponatremia]] | ||
|- | |- | ||
| SALTIRE | | [[SALTIRE]] | ||
| [[Scottish Aortic Stenosis And Lipid Lowering Trial]] | | [[Scottish Aortic Stenosis And Lipid Lowering Trial]] | ||
|- | |- | ||
| SANDS | | [[SANDS]] | ||
| [[Stop Atherosclerosis In Native Diabetics Study]] | | [[Stop Atherosclerosis In Native Diabetics Study]] | ||
|- | |- | ||
| SAPAT | | [[SAPAT]] | ||
| [[Double-Blind Trial Of Aspirin In Primary Prevention Of Myocardial Infarction In Patients With Stable Chronic Angina Pectoris]] | | [[Double-Blind Trial Of Aspirin In Primary Prevention Of Myocardial Infarction In Patients With Stable Chronic Angina Pectoris]] | ||
|- | |- | ||
| SAPPHIRE | | [[SAPPHIRE]] | ||
| [[Stenting And Angioplasty With Protection In Patients At High Risk For Endarterectomy]] | | [[Stenting And Angioplasty With Protection In Patients At High Risk For Endarterectomy]] | ||
|- | |- | ||
| SARECCO | | [[SARECCO]] | ||
| [[Stent Or Angioplasty After Recanalization Of Chronic Coronary Occlusions Trial]] | | [[Stent Or Angioplasty After Recanalization Of Chronic Coronary Occlusions Trial]] | ||
|- | |- | ||
| SAVE | | [[SAVE]] | ||
| [[Survival And Ventricular Enlargement Trial]] | | [[Survival And Ventricular Enlargement Trial]] | ||
|- | |- | ||
| SAVE PACe | | [[SAVE PACe]] | ||
| [[Search Av Extension And Managed Ventricular Pacing For Promoting Atrioventricular Conduction]] | | [[Search Av Extension And Managed Ventricular Pacing For Promoting Atrioventricular Conduction]] | ||
|- | |- | ||
| SAVED | | [[SAVED]] | ||
| [[Saphenous Vein De Novo]] | | [[Saphenous Vein De Novo]] | ||
|- | |- | ||
| SCANDSTENT | | [[SCANDSTENT]] | ||
| [[Stenting Of Coronary Arteries In Non Stress/Benestent Disease Trial]] | | [[Stenting Of Coronary Arteries In Non Stress/Benestent Disease Trial]] | ||
|- | |- | ||
| SCAT | | [[SCAT]] | ||
| [[Long-Term Effects Of Cholesterol Lowering And Angiotension-Converting Enzyme Inhibition On Coronary Atherosclerosis. The Simvastatin/Enalapril Coronary Atherosclerosis Trial (Scat).]] | | [[Long-Term Effects Of Cholesterol Lowering And Angiotension-Converting Enzyme Inhibition On Coronary Atherosclerosis. The Simvastatin/Enalapril Coronary Atherosclerosis Trial (Scat).]] | ||
|- | |- | ||
| SCD-HeFT | | [[SCD-HeFT]] | ||
| [[Sudden Cardiac Death In Heart Failure Trial]] | | [[Sudden Cardiac Death In Heart Failure Trial]] | ||
|- | |- | ||
| SCOR | | [[SCOR]] | ||
| [[University Of California, San Francisco, Arteriosclerosis Specialized Center Of Research (Scor) Intervention Trial]] | | [[University Of California, San Francisco, Arteriosclerosis Specialized Center Of Research (Scor) Intervention Trial]] | ||
|- | |- | ||
| SCORE | | [[SCORE]] | ||
| [[Study To Compare Restenosis Rate Between Quest And Quadds-Qp2]] | | [[Study To Compare Restenosis Rate Between Quest And Quadds-Qp2]] | ||
|- | |- | ||
| SCRIP | | [[SCRIP]] | ||
| [[Study Of Cardiovascular Risk Intervention By Pharmacists]] | | [[Study Of Cardiovascular Risk Intervention By Pharmacists]] | ||
|- | |- | ||
| SCRIPPS | | [[SCRIPPS]] | ||
| [[Scripps Coronary Radiation To Inhibit Proliferation Post Stenting]] | | [[Scripps Coronary Radiation To Inhibit Proliferation Post Stenting]] | ||
|- | |- | ||
| SCRIPPS II | | [[SCRIPPS II]] | ||
| [[Scripps Coronary Radiation To Inhibit Proliferation Post Stenting II]] | | [[Scripps Coronary Radiation To Inhibit Proliferation Post Stenting II]] | ||
|- | |- | ||
| SCRIPPS III | | [[SCRIPPS III]] | ||
| [[Scripps Coronary Radiation To Inhibit Proliferation Post Stenting III]] | | [[Scripps Coronary Radiation To Inhibit Proliferation Post Stenting III]] | ||
|- | |- | ||
| SCRIPPS IV | | [[SCRIPPS IV]] | ||
| [[Scripps Coronary Radiation To Inhibit Proliferation Post Stenting Iv]] | | [[Scripps Coronary Radiation To Inhibit Proliferation Post Stenting Iv]] | ||
|- | |- | ||
| SEARCH | | [[SEARCH]] | ||
| [[Study Of The Effectiveness Of Additional Reductions In Cholesterol And Homocysteine]] | | [[Study Of The Effectiveness Of Additional Reductions In Cholesterol And Homocysteine]] | ||
|- | |- | ||
| SEAS | | [[SEAS]] | ||
| [[Simvastatin And Ezetimibe In Aortic Stenosis]] | | [[Simvastatin And Ezetimibe In Aortic Stenosis]] | ||
|- | |- | ||
| SECURE | | [[SECURE]] | ||
| [[Study To Evaluate Carotid Ultrasound Changes In Patients Treated With Ramipril And Vitamin E]] | | [[Study To Evaluate Carotid Ultrasound Changes In Patients Treated With Ramipril And Vitamin E]] | ||
|- | |- | ||
| SEEDS | | [[SEEDS]] | ||
| [[Syncope Evaluation In The Emergency Department Study]] | | [[Syncope Evaluation In The Emergency Department Study]] | ||
|- | |- | ||
| SEISMIC | | [[SEISMIC]] | ||
| [[Safety And Effects Of Implanted (Autologous) Skeletal Myoblasts (Myocell) Using An Injection Catheter]] | | [[Safety And Effects Of Implanted (Autologous) Skeletal Myoblasts (Myocell) Using An Injection Catheter]] | ||
|- | |- | ||
| SENIOR PAMI | | [[SENIOR PAMI]] | ||
| [[Senior Primary Angioplasty In Myocardial Infarction Study]] | | [[Senior Primary Angioplasty In Myocardial Infarction Study]] | ||
|- | |- | ||
| SENIORS | | [[SENIORS]] | ||
| [[Study Of Effects Of Nebivolol Intervention On Outcomes And Rehospitalisation In Seniors With Heart Failure]] | | [[Study Of Effects Of Nebivolol Intervention On Outcomes And Rehospitalisation In Seniors With Heart Failure]] | ||
|- | |- | ||
| SESAIR | | [[SESAIR]] | ||
| [[Randomised Comparison Of Subcutaneous Heparin, Intravenous Heparin, And Aspirin In Unstable Angina]] | | [[Randomised Comparison Of Subcutaneous Heparin, Intravenous Heparin, And Aspirin In Unstable Angina]] | ||
|- | |- | ||
| SESAMI | | [[SESAMI]] | ||
| [[Sirolimus-Eluting Stent Versus Bare-Metal Stent In Acute Myocardial Infarction]] | | [[Sirolimus-Eluting Stent Versus Bare-Metal Stent In Acute Myocardial Infarction]] | ||
|- | |- | ||
| SES-SMART | | [[SES-SMART]] | ||
| [[Sirolimus-Eluting Stent And A Standard Stent In The Prevention Of Restenosis In Small Coronary Arteries]] | | [[Sirolimus-Eluting Stent And A Standard Stent In The Prevention Of Restenosis In Small Coronary Arteries]] | ||
|- | |- | ||
| SHARP | | [[SHARP]] | ||
| [[The Subcutaneous Heparin And Angioplasty Restenosis Prevention (Sharp) Trial. Results Of A Multicentre Randomized Trial Investigating The Effects Of High Dose Unfractionated Heparin On Angiographic Restenosis And Clinical Outcome]] | | [[The Subcutaneous Heparin And Angioplasty Restenosis Prevention (Sharp) Trial. Results Of A Multicentre Randomized Trial Investigating The Effects Of High Dose Unfractionated Heparin On Angiographic Restenosis And Clinical Outcome]] | ||
|- | |- | ||
| SHEP | | [[SHEP]] | ||
| [[Systolic Hypertension In Elderly Program]] | | [[Systolic Hypertension In Elderly Program]] | ||
|- | |- | ||
| SHIELD | | [[SHIELD]] | ||
| [[Shock Inhibition Evaluation With Azimilide]] | | [[Shock Inhibition Evaluation With Azimilide]] | ||
|- | |- | ||
| SHOCK | | [[SHOCK]] | ||
| [[Should We Emergently Revascularize Occluded Coronaries For Cardiogenic Shock?]] | | [[Should We Emergently Revascularize Occluded Coronaries For Cardiogenic Shock?]] | ||
|- | |- | ||
| SIAM | | [[SIAM]] | ||
| [[Comparison Of Invasive And Conservative Strategies After Treatment With Streptokinase In Acute Myocardial Infarction]] | | [[Comparison Of Invasive And Conservative Strategies After Treatment With Streptokinase In Acute Myocardial Infarction]] | ||
|- | |- | ||
| SIAM III | | [[SIAM III]] | ||
| [[Southwest German Interventional Study In Acute Myocardial Infarction]] | | [[Southwest German Interventional Study In Acute Myocardial Infarction]] | ||
|- | |- | ||
| SICCO | | [[SICCO]] | ||
| [[Stenting In Chronic Coronary Occlusion]] | | [[Stenting In Chronic Coronary Occlusion]] | ||
|- | |- | ||
| SIMPADICO | | [[SIMPADICO]] | ||
| [[Study Of Immune Modulation Therapy In Patients With Symptomatic Peripheral Arterial Disease]] | | [[Study Of Immune Modulation Therapy In Patients With Symptomatic Peripheral Arterial Disease]] | ||
|- | |- | ||
| SIPS | | [[SIPS]] | ||
| [[Ultrasound-Guided Stratification For Provisional Stenting With Focal Balloon Combination Catheter. Results From The Randomized Strategy For Intracoronary Ultrasound-Guided Ptca And Stenting (Sips) Trial]] | | [[Ultrasound-Guided Stratification For Provisional Stenting With Focal Balloon Combination Catheter. Results From The Randomized Strategy For Intracoronary Ultrasound-Guided Ptca And Stenting (Sips) Trial]] | ||
|- | |- | ||
| SIRIUS | | [[SIRIUS]] | ||
| [[Sirolimus-Eluting Stent In Coronary Lesions]] | | [[Sirolimus-Eluting Stent In Coronary Lesions]] | ||
|- | |- | ||
| SIRIUS-2 | | [[SIRIUS-2]] | ||
| [[Safety And Efficacy Of An Intravenous Placebo-Controlled Randomized Infusion Of Ularitide]] | | [[Safety And Efficacy Of An Intravenous Placebo-Controlled Randomized Infusion Of Ularitide]] | ||
|- | |- | ||
| SIRTAX | | [[SIRTAX]] | ||
| [[Sirolimus-Eluting Stent Compared With Paclitaxel-Eluting Stent For Coronary Revascularization]] | | [[Sirolimus-Eluting Stent Compared With Paclitaxel-Eluting Stent For Coronary Revascularization]] | ||
|- | |- | ||
| SISR | | [[SISR]] | ||
| [[Sirolimus-Eluting Stent Vs. Brachytherapy In Patients With Bare Metal In-Stent Restenosis]] | | [[Sirolimus-Eluting Stent Vs. Brachytherapy In Patients With Bare Metal In-Stent Restenosis]] | ||
|- | |- | ||
| SLIP | | [[SLIP]] | ||
| [[Lipid Profile During Antihypertensive Treatment]] | | [[Lipid Profile During Antihypertensive Treatment]] | ||
|- | |- | ||
| SMART | | [[SMART]] | ||
| [[Surgical Management Of Arterial Revascularization Therapies]] | | [[Surgical Management Of Arterial Revascularization Therapies]] | ||
|- | |- | ||
| SMART | | [[SMART]] | ||
| [[Sirolimus-Eluting Stents For The Treatment Of Obstructive Superficial Femoral Artery Disease]] | | [[Sirolimus-Eluting Stents For The Treatment Of Obstructive Superficial Femoral Artery Disease]] | ||
|- | |- | ||
| SMARTT | | [[SMARTT]] | ||
| [[A Randomized Trial Of The Effects Of Early Cardiac Serum Marker Availability On Reperfusion Therapy In Patients With Acute Myocardial Infarction. The Serial Markers, Acute Myocardial Infarction And Rapid Treatment Trial (Smartt)]] | | [[A Randomized Trial Of The Effects Of Early Cardiac Serum Marker Availability On Reperfusion Therapy In Patients With Acute Myocardial Infarction. The Serial Markers, Acute Myocardial Infarction And Rapid Treatment Trial (Smartt)]] | ||
|- | |- | ||
| SMASH-VT | | [[SMASH-VT]] | ||
| [[Substrate Mapping And Ablation In Sinus Rhythm To Halt Ventricular Tachycardia]] | | [[Substrate Mapping And Ablation In Sinus Rhythm To Halt Ventricular Tachycardia]] | ||
|- | |- | ||
| SMILE | | [[SMILE]] | ||
| [[The Effects Of The Angiotensin-Converting-Enzyme Inhibitor Zofenopril On Mortality And Morbidity After Anterior Myocardial Infarction]] | | [[The Effects Of The Angiotensin-Converting-Enzyme Inhibitor Zofenopril On Mortality And Morbidity After Anterior Myocardial Infarction]] | ||
|- | |- | ||
| SMT | | [[SMT]] | ||
| [[Stockholm Metoprolol Trial]] | | [[Stockholm Metoprolol Trial]] | ||
|- | |- | ||
| SOFA | | [[SOFA]] | ||
| [[Study On Omega-3 Fatty Acids And Ventricular Arrhythmia]] | | [[Study On Omega-3 Fatty Acids And Ventricular Arrhythmia]] | ||
|- | |- | ||
| SOLVD-Treatment | | [[SOLVD-Treatment]] | ||
| [[The Effects Of Enalapril On Survival In Patients With Reduced Left Ventricular Ejection Fractions And Congestive Heart Failure (Treatment Trial)]] | | [[The Effects Of Enalapril On Survival In Patients With Reduced Left Ventricular Ejection Fractions And Congestive Heart Failure (Treatment Trial)]] | ||
|- | |- | ||
| SORT OUT II | | [[SORT OUT II]] | ||
| [[Comparison Of Paclitaxel- And Sirolimus-Eluting Stents In Everyday Clinical Practice]] | | [[Comparison Of Paclitaxel- And Sirolimus-Eluting Stents In Everyday Clinical Practice]] | ||
|- | |- | ||
| SoS | | [[SoS]] | ||
| [[Coronary Artery Bypass Surgery Vs. Percutaneous Coronary Intervention With Stent Implantation In Patients With Multivessel Coronary Disease (The Stent Or Surgery Trial)]] | | [[Coronary Artery Bypass Surgery Vs. Percutaneous Coronary Intervention With Stent Implantation In Patients With Multivessel Coronary Disease (The Stent Or Surgery Trial)]] | ||
|- | |- |
Revision as of 16:08, 24 June 2009
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
For other acronyms involved in clinical trials, click here
For detailed instructions on how to contribute to WikiDoc's Clinical Trials Wiki, click here